PERSONAL INFORMATION Anthony Wierzbicki Head of … · Curriculum vitae Anthony Wierzbicki and Translational Biology, and Council on Lifestyle and Cardiometabolic Health. The Agenda

Curriculum vitae

PERSONAL INFORMATION Anthony Wierzbicki

WORK EXPERIENCE

February 1995–Present Consultant in Metabolic Medicine/Chemical PathologyGuy's & St Thomas Hospitals Trust (United Kingdom)

Honorary Professor of Cardiometabolic Disease (King's College London)

Head of Unit: Lipid clinic.

Consultant Physician: obesity clinic

Consultant Physician: Adult peroxisomal disorders (Refsum) Clinic, Chelsea & Westminster Hospital

Head of Department: Blood Sciences Laboratory GSTT later GSTS Pathology

October 1993–February 1995 Lecturer (honorary senior registrar) in Chemical PathologyImperial College Hospitals London (United Kingdom)

Academic lecturer in Chemical Pathology/Clinical Biochemistry

Attachments to lipid and hypertension units

September 1992–October 1993 Registrar in Medical BiochemsistyUniversity Hospital of Wales, Cardiff (United Kingdom)

Training in Chemical Pathology/Clinical Biochemistry

Attachments to lipid and porphyria units

September 1989–September1992

Research FellowMRC Research Fellow; Weatherall Institute University of Oxford (United Kingdom)

Basic science research on calcium channels in Lambert-Eaton myasthenic syndrome


Senior House OfficerNational Hospital for Neurology & Neurosurgery London (United Kingdom)

Training in clinical biochemistry, haematology and microbiology

February 1987–September 1987 House OfficerTreliske Hospital, Truro, Cornwall (United Kingdom)

Basic medical internship in general, renal and elderly care medicine

August 1986–January 1987 House OfficerRiyal Shrewsbury Hospital, Shrewsbury, Shropshire (United Kingdom)

Basic surgical internship in general and vascular surgery

EDUCATION AND TRAINING

October 1980–July 1983 BA & MAUniversity of Cambridge (United Kingdom)

Medical sciences undergraduate curriculum; natural sciences research programme in immunology

September 1983–July 1986 BMBChUniversity of Oxford (United Kingdom)

23/8/19 © European Union, 2002-2019 | http://europass.cedefop.europa.eu Page 1 / 27

Curriculum vitae Anthony Wierzbicki

Clinical medical training


DPhilUniversity of Oxford (United Kingdom)

Basic science research on the molecular biology of calcium channels in Lambert-Eaton myasthenic syndrome

October 1994–July 2004 DMUniversity of Oxford (United Kingdom)

Clinical, biochemical and molecular genetics of adult Refsum disease

–2001 FRCPathRoyal College of Pathologists (United Kingdom)

Certificate of Specialist training in Chemical Pathology

ADDITIONAL INFORMATION

Expertise My clinical and research interests are

1. Lipids in atherosclerosis

2. Lipids in peroxisomal diseases and other inborn erors of metabolism.

3. Obesity medicine

4. Clinical Biochemistry of cardiovascular and metabolic biomarkers

Publications Publications:

Guidelines

1. Wierzbicki AS, Humphries SE, Minhas R; Guideline Development Group. Familial hypercholesterolaemia: summary of NICE guidance. BMJ. 2008 Aug 27;337:a1095

2. Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, Bruckert E, Defesche J, Lin KK,Livingston M, Mata P, Parhofer KG, Raal FJ, Santos RD, Sijbrands EJ, Simpson WG, Sullivan DR, Susekov AV, Tomlinson B, Wiegman A, Yamashita S, Kastelein JJ. Integrated guidance on the care offamilial hypercholesterolaemia from the International FH Foundation. Int J Cardiol. 2014 Feb 15;171(3):309-2

3. Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, Bruckert E, Defesche J, Lin KK,Livingston M, Mata P, Parhofer KG, Raal FJ, Santos RD, Sijbrands EJ, Simpson WG, Sullivan DR, Susekov AV, Tomlinson B, Wiegman A, Yamashita S, Kastelein JJ. Integrated guidance on the care offamilial hypercholesterolaemia from the International FH Foundation. J Clin Lipidol. 2014 Mar-Apr;8(2):148-72

4. Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, Bruckert E, Defesche J, Lin KK,Livingston M, Mata P, Parhofer KG, Raal FJ, Santos RD, Sijbrands EJ, Simpson WG, Sullivan DR, Susekov AV, Tomlinson B, Wiegman A, Yamashita S, Kastelein JJ. Integrated guidance on the care offamilial hypercholesterolaemia from the International FH Foundation. Eur J Prev Cardiol. 2015 Jul;22(7):849-54

5. Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, Bruckert E, Defesche J, Lin KK,Livingston M, Mata P, Parhofer KG, Raal FJ, Santos RD, Sijbrands EJ, Simpson WG, Sullivan DR, Susekov AV, Tomlinson B, Wiegman A, Yamashita S, Kastelein JJ. Integrated guidance on the care offamilial hypercholesterolaemia from the International FH Foundation. J Atheroscler Thromb. 2014;21(4):368-74.

6. Rabar S, Harker M, O'Flynn N, Wierzbicki AS; Guideline Development Group. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ. 2014 Jul 17;349:g4356

7. Gidding SS, Champagne MA, de Ferranti SD, Defesche J, Ito MK, Knowles JW, McCrindle B, Raal F, Rader D, Santos RD, Lopes-Virella M, Watts GF, Wierzbicki AS; American Heart Association Atherosclerosis, Hypertension, and Obesity in Young Committee of Council on Cardiovascular Disease in Young, Council on Cardiovascular and Stroke Nursing, Council on Functional Genomics



and Translational Biology, and Council on Lifestyle and Cardiometabolic Health. The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. Circulation. 2015 Dec 1;132(22):2167-92. Erratum in: Circulation. 2015 Dec 22;132(25):e397.

8. Real J, Cowles E, Wierzbicki AS; Guideline Committee. Chronic heart failure in adults: summary of updated NICE guidance. BMJ. 2018 Sep 24;362:k3646

Reviews:

1. Wierzbicki AS. The role of polymerase chain reaction in the routine clinical laboratory

Commun Lab Med 1993; 5 : 95-102

2. Wierzbicki AS. Fybozest-orange: a new treatment for mild primary hypercholesterolaemia. Prescriber 1997; 8 (10): 35-42

3. Wierzbicki AS. Diagnosis and management of hyperlipidaemia. Int J Clin Practice 1997; 51 : 378-83

4. Wierzbicki AS. Laboratory investigations by DNA amplification: from research to practice. Ann Clin Biochem 1998; 35 : 5-12

5. Wierzbicki AS. Role of lipid lowering in transplantation. Int J Clin Practice 1999; 53: 54-59

6. Wierzbicki AS, Shetty CR. Aortic stenosis. An atherosclerotic disease? J Heart Valve Disease 1999;8 : 416-23

7. Christ ER, Wierzbicki AS, Cummings MH, Umpleby AM, Russell-Jones DL. Dynamics of lipoproteinmetabolism in adult growth hormone deficiency (GHD). J Endocrine Invest 1999; 22 :16-21

8. Wierzbicki AS. Familial hypercholesterolaemia. Coronary Health Care 2000; 4 : 192-197

9. Wierzbicki AS. Managing hyperlipidaemia as part of cardiovascular risk. Cardiac and Critical Care Journal 2000; (2) : 3

10. Wierzbicki AS. The role of lipid-lowering therapy in the management of cardiovascular disease in SLE. Lupus 2000; 9:194-201

11. Mikhailidis DP, Wierzbicki AS. HDL Cholesterol and the treatment of coronary heart disease. Curr Med Res Opinion 2000; 16 : 139-46

12. Wierzbicki AS. The effects of oral contraceptives and hormone replacement therapy on lipids. Gynaecology Forum 2000; 5 : 11-14

13. Wierzbicki AS. Lipid-lowering drugs in lupus: an unexplored therapeutic intervention. Lupus 2001 : 10 : 233-236

14. Wierzbicki AS. Atorvastatin. Exp Opin Pharmacother 2001; 2: 819-830

15. Wierzbicki AS, Mikhailidis DP, Wray R. Drug treatment of combined hyperlipidemia. Am J Cardiovasc Drugs 2001; 1 : 327-336

16. Nair DR, Wierzbicki AS, Mikhailidis DP. Time to look beyond just lowering the concentration of low density lipoprotein (LDL)- high density lipoprotein (HDL) levels are also important. J Roy Soc Health 2001; 121 : 98-101

17. Wierzbicki AS. Lipid-lowering in the elderly. Curr Med Lit (Health Care of Older People) 2001; 14 : 87-92

18. Wierzbicki AS, Lloyd MD, Schofield CJ, Feher MD, Gibberd FB. Refsum’s disease: a peroxisomal disorder affecting alpha-oxidation of phytanic acid: a mini-review. J Neurochem 2002; 80 : 727-735

19. Wierzbicki AS, Mikhailidis DP. Beyond LDL-C- the importance of raising HDL-C. Curr Med Res Opinion 2002; 18 : 36-44

20. Wierzbicki AS, Mikahailidis DP. Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of 5 studies. Int J Cardiol 2002; 84 : 53-57

21. Wierzbicki AS. Stroke in systemic lupus erythematosus. Exp Rev Neurotherapeutics 2002; 2 : 89-94

22. Wierzbicki AS. Lower = better. The real benefits of lowering cholesterol even further. Brit J Cardiol 2002; 9 Suppl 1: S6-7

23. Wierzbicki AS. Lipid-lowering. Another method of reducing blood pressure? J Hum Hypertens 2002; 16 : 753-760

24. Frank M. Sacks and Expert Group on HDL Cholesterol .The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002; 90 : 139-143

25. Wierzbicki AS. Statin therapy in people with diabetes and high-risk patients. Hospital Medicine



2003; 64 : 16-19

26. Wierzbicki AS. New lipid-lowering agents. Expert Opin Emerg Drugs 2003; 8 : 365-76

27. Mukherji M, Schofield CJ, Wierzbicki AS, Jansen GA, Wanders RJA, Lloyd MD. The Chemical Biology of Branched-Chain Lipid Metabolism. Prog Lipid Res 2003; 42 : 359-376

28. Wierzbicki AS, Mikhailidis DP, Wray R, Schachter M, Cramb R, Simpson WB, Byrne CB. Statin and fibrate combination therapy for hyperlipidaemia: a review. Curr Med Res Opin 2003; 19 : 155-168

29. Wierzbicki AS, Poston RN, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003; 99 : 95-112

30. Solomon H, Man J, Wierzbicki AS, O'Brien T, Jackson G. Erectile dysfunction: cardiovascular risk and the role of the cardiologist. Int J Clin Pract. 2003; 57 : 96-99

31. Twomey PJ, Wierzbicki AS, Reynolds TM. Issues to consider when attempting to achieve the American Diabetes Association clinical quality requirement for A1C. Curr Med Res Opin 2003; 19 : 719-23

32. Wierzbicki AS. Targeting multiple pathways in cholesterol management. Brit J Cardiol 2004; 11 suppl 3; S11-13

33. Wierzbicki AS. Lipid-altering drugs: the future. Int J Clin Pract 2004; 58 : 1063-1072

34. HDL Consensus Group. The importance of raising HDL-C. Curr Med Res Opin 2004; 20 : 241-247

35. Twomey P, Wierzbicki AS, Reynolds TM. The casino of life: markets, mathematics and medicine. JClin Path 2004; 57 : 243-244

36. Chapman MJ, Assman G, Fruchart J-C, Shepherd J, Sirtori C on behalf of the European Consensus Panel on HDL-C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid- a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004; 20 : 1253-1268

37. Wierzbicki AS. Raising high-density lipoprotein. Int J Clin Pract 2004; 58 : 817-819

38. Wierzbicki AS. Lipid lowering therapies in development. Exp Opin Investig Drugs 2004; 13 : 1405-1418

39. Liberopoulos EN, Daskalopoulou S, Mikhailidis DP, Wierzbicki AS, Elisaf MS. A review of the lipid-related effects of fluvastatin. Curr Med Res Opin 2005; 21 : 231-243

40. Wierzbicki AS. Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention? Curr Med Res Opin 2005; 21 : 299-305

41. Mikhailidis DP, Wierzbicki AS, Daskalopoulo SS, Al-Saady N, Griffiths H, Hamilton G, Monkman D,Patel V, Pittard J, Schachter M. The use of ezetimibe in achieving low-density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr Med Res Opin 2005; 21 : 959-970

42. Wierzbicki AS. The role of dyslipidaemia in coronary heart disease. Brit J Diab Vasc Dis 2005; 5 suppl 1; S2-S6

43. Kulasegaram R, Peters BS, Wierzbicki AS. Dyslipidaemia and cardiovascular risk in HIV infection. Curr Med Res Opin 2005; 21 : 1717-1725

44. Wierzbicki AS. FIELDs of dreams, fields of tears: a perspective on the fibrate trials. Int J Clin Pract 2006; 60 : 442-9

45. Wierzbicki AS. Managing HDL-C. MiMS Cardiology 2006 ; in press

46. Wierzbicki AS. Future approaches to reducing low-density lipoprotein cholesterol. Future Lipidol 2006; 1 : 463-477

47. (Wierzbicki AS). Statins for primary prevention in type 2 diabetes. Drug & Therapeutics Bulletin 2006; 44 ; 57-64

48. Wierzbicki AS. Diabetic dyslipidaemia: the triad. Eur Heart J 2006; 8 suppl F: F30-F33

49. Pedersen TR, Assmann G, Bassand J-P, Chapman MJ, Erbel B, Sirtori C on behalf of the European Expert Panel. Reducing residual cardiovascular risk: the relevance of raising high-density lipoprotein cholesterol in patients on cholesterol-lowering treatment. A position paper. Diab Vasc Dis Res 2006; 3 suppl 2 : S1-S12

50. Wierzbicki AS. Rimonabant: endocannabinoid inhibition for the metabolic syndrome. Int J Clin Pract 2006; 60: 1697-1706

51. Wierzbicki AS. Fibrates after the FIELD study: some answers, more questions. Diab Vasc Dis 2006; 33 : 166-171

52. Wierzbicki AS. Lipid-altering therapies and the progression of atherosclerotic disease. Cardiovasc



Intervent Radiol 2007; 30: 155-60

53. Wierzbicki AS, Purdon SD, Hardman TC, Kulasegaram R, Peters BS. HIV lipodystrophy- a cardiometabolic disease? Implications for clinical practice. Curr Med Res Opin 2008; 24 : 609-24

54. Wierzbicki AS. Low HDL-cholesterol- is modification called for? Cardiometabolic Risk 2007; 2: in press

55. Wierzbicki AS.Homocysteine and cardiovascular disease: a review of the evidence. Diab Vasc DisRes. 2007 Jun;4(2):143-50

56. Wierzbicki AS. Voodoo medicine- cardiovascular trials jinxed in New Orleans. Report of the 56th annual meeting of the American College of Cardiology held in New Orleans 24-27 March 2007. Brit J Diabetes Vasc Dis 2007; 7 : 142-4

57. Wierzbicki AS. Peroxisomal disorders affecting phytanic acid alpha-oxidation: a review. Biochem Soc Trans. 2007 Nov; 35 (Pt 5):881-6

58. Wierzbicki AS, Purdon SD, Hardman TC, Kulasegaram R, Peters BS. HIV lipodystrophy and its metabolic consequences: implications for clinical practice. Curr Med Res Opin. 2008 Mar; 24(3):609-24

59. Wierzbicki AS, Graham CA, Young IS, Nicholls DP. Familial combined hyperlipidaemia: under - defined and under - diagnosed? Curr Vasc Pharmacol. 2008 Jan;6(1):13-22

60. Lloyd MD, Darley DJ, Wierzbicki AS, Threadgill MD. Alpha-methylacyl-CoA racemase--an 'obscure' metabolic enzyme takes centre stage. FEBS J. 2008 Mar; 275(6):1089-102

61. Viljoen A, Wierzbicki AS. New approaches in the diagnosis of atherosclerosis and treatment of cardiovascular disease. Recent Patents Cardiovasc Drug Disc 2008; 3 : 84-91

62. Wierzbicki AS, Purdon SD, Hardman TC, Kulasegaram R, Peters BS. Clinical aspects of the management of HIV lipodystrophy. Brit J Diab Vasc Dis 2008; 8 : 113-9

63. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol. 2008 Jul;23(4):370-8

64. Wierzbicki AS. Surrogate markers, atherosclerosis and cardiovascular disease prevention. Int J Clin Pract. 2008 Jul; 62(7) : 981-987

65. Wierzbicki AS. A fishy business: omega-3 fatty acids and cardiovascular disease. Int J Clin Pract 2008 Aug ; 62(8) : 1142-1146

66. Wierzbicki AS. Muddy waters: more stormy SEAS for ezetimibe. Int J Clin Pract 2008 Oct 62 (10) :1470-1473

67. Wierzbicki AS, Humphries SE, Minhas R. Familial hypercholesterolaemia; a summary of the NICEguidance. Brit Med J 2008; 337 ; a1095

68. Wierzbicki AS.Interpreting clinical trials of diabetic dyslipidaemia: new insights. Diabetes Obes Metab. 2009 (3) ; 11: 261-70

69. Athyros VG, Kakafika AI, Wierzbicki AS, Karagiannis A, Mikhailidis DP. Targeting triglycerides in secondary prevention: should we bother? Int J Clin Pract. 2009 Jan;63(1):15-8

70. Wierzbicki AS. Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. CurrOpin Cardiol 2009; 24(4):372-9.

71. Viljoen A, Wierzbicki AS. Potential Options to Treat Hypertriglyceridaemia. Current Drug Targets 2009; 10 (4) : 356-362

72. Wierzbicki AS, Hardman T, Prince WT. Future Challenges for Microsomal Transport Protein Inhibitors. Curr Vasc Pharmacol 2009; 7 (3): 277-286

73. Wierzbicki AS, Reynolds TM. Vascular risk screening: possible or too much, too soon? Int J Clin Pract. 2009 Jan;63(7):989-996

74. Ara R, Rafia R, Ward SE, Wierzbicki AS, Reynolds TM, Rees A, Pandor A. Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective. Expert Rev Pharmacoecon Outcomes Res. 2009 Oct; 9(5):423-33

75. Viljoen A, Wierzbicki AS. Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia. Drug Healthcare Patient Safety 2010; 2 (2): 61-71

76. Wierzbicki AS, Viljoen A Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice. Drug Saf. 2010;33(2):115-25

77. Athyros VG, Tziomalos K, Karagiannis A, Wierzbicki AS, Mikhailidis DP. Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association? Curr Opin Cardiol. 2010 Jul; 25(4): 406-10.



78. Wierzbicki AS, Viljoen A, Chambers JB. Aortic stenosis and lipids: does intervention work? Curr Opin Cardiol. 2010 Jul; 25(4): 379-84.

79. Wierzbicki AS. Fibrates: no ACCORD on their use in the treatment of dyslipidaemia. Curr Opin Lipidol. 2010 Aug; 21(4):352-8

80. Rüether K, Baldwin E, Casteels M, Feher MD, Horn M, Kuranoff S, Leroy BP, Wanders RJ, Wierzbicki AS. Adult Refsum Disease: A Form of Tapetoretinal Dystrophy Accessible to Therapy. SurvOphthalmol. 2010 November - December; 55(6):531-538

81. Hardman TC, Rutherford P, Dubrey SW, Wierzbicki AS. Sodium-Glucose Co-transporter 2 Inhibitors: From Apple Tree to 'Sweet Pee'. Curr Pharm Des. 2010; 16(34):3830-8

82. Billups KL, Miner MM, Wierzbicki AS, Jackson G. Gender-based cardiometabolic risk evaluation inminority and non-minority men grading the evidence of non-traditional determinants of cardiovascular risk. Int J Clin Pract. 2011 Feb;65(2):134-47

83. Rizzo M, Wierzbicki AS. New lipid modulating drugs: the role of microsomal transport protein inhibitors. Curr Pharm Des. 2011;17(9):943-9

84. Kolovou G, Kolovou V, Vasiliadis I, Wierzbicki AS, Mikhailidis DP. Ideal lipid profile and genes for an extended life span. Curr Opin Cardiol. 2011 Jul;26(4):348-55

85. Katsiki N, Wierzbicki AS, Mikhailidis DP. Pulmonary arterial hypertension and statins: an update. Curr Opin Cardiol. 2011 Jul;26(4):322-6

86. Mikhailidis DP, Elisaf M, Rizzo M, Berneis K, Griffin B, Zambon A, Athyros V, de Graaf J, März W, Parhofer KG, Rini GB, Spinas GA, Tomkin GH, Tselepis AD, Wierzbicki AS, Winkler K, Florentin M, Liberopoulos E. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011 Sep 1;9(5):533-71

87. Mikhailidis DP, Elisaf M, Rizzo M, Berneis K, Griffin B, Zambon A, Athyros V, de Graaf J, März W, Parhofer KG, Rini GB, Spinas GA, Tomkin GH, Tselepis AD, Wierzbicki AS, Winkler K, Florentin M, Liberopoulos E. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol. 2011 Sep 1;9(5):531-2

88. Viljoen A, Wierzbicki AS. Investigating mixed hyperlipidaemia. BMJ. 2011 Aug 25;343:d5146

89. Khavandi K, Brownirgg J, Hankir M, Sood H, Younis N, Worth J, Greenstein A, Soran H, Wierzbicki AS, Goldsmith DJ. Interrupting the Natural History of Diabetes Mellitus: Lifestyle, Pharmacological and Surgical Strategies Targeting Disease Progression. Curr Vasc Pharmacol. 2012 Jan 20

90. Wierzbicki AS, Hardman TC, Viljoen A. Lipid–lowering Drugs in development: an update. Int J ClinPract 2012; 66(3): 270-80

91. Wierzbicki AS, Hardman TC, Viljoen A. Strategies and drugs to inhibit pre-protein convertase serine kexin-9 (PCSK-9). Exp Opin Invest Drugs 2012; May;21(5):667-76.

92. Viljoen A, Wierzbicki AS. Diagnosis and treatment of severe hypertriglyceridemia. Expert Rev Cardiovasc Ther. 2012 Apr;10(4):505-14.

93. Wierzbicki AS New directions in cardiovascular risk assessment: the role of secondary risk stratification markers. Int J Clin Pract. 2012 Jul;66(7):622-30

94. Wierzbicki AS, Oben J. Nonalcoholic fatty liver disease and lipids. Curr Opin Lipidol. 2012 Aug;23(4):345-52

95. Wierzbicki AS, Clarke RE, Viljoen A, Mikhailidis DP. Triglycerides: a case for treatment? Curr Opin Cardiol. 2012 Jul;27(4):398-404

96. Paraskevas KI, Wierzbicki AS, Mikhailidis DP. Statins and noncardiac vascular disease. Curr Opin Cardiol. 2012 Jul;27(4):392-7

97. Wierzbicki AS, Viljoen A. Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency. Expert Opin Biol Ther. 2013 Jan;13(1):7-10

98. Peters B, Post F, Wierzbicki A, Phillips A, Power L, Das S, Johnson M, Moyle G, Hughes L, Wilkins E, McCloskey E, Compston J, Di Angelantonio E. Screening for chronic co-morbid diseases inpeople with HIV: the need for a strategic approach. HIV Med. 2013 Jan;14 Suppl 1:1-11

99. Scarisbrick JJ, Morris S, Azurdia R, Illidge T, Parry E, Graham-Brown R, Cowan R, Gallop-Evans E, Wachsmuth R, Eagle M, Wierzbicki AS, Soran H, Whittaker S, Wain EM. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol. 2013 Jan;168(1):192-200

100. Peters B, Post F, Wierzbicki AS, Phillips A, Power L, Das S, Johnson M, Moyle G, Hughes L,



Wilkins E, McCloskey E, Compston J, Di Angelantonio E. Screening for chronic comorbid diseases in people with HIV: the need for a strategic approach. HIV Med. 2013 Jan;14 Suppl 1:1-11

101. Wierzbicki AS, Viljoen A, Hardman TC, Mikhailidis DP New therapies to reduce low-density lipoprotein cholesterol. Curr Opin Cardiol. 2013 Jul;28(4):452-7

102. Katsiki N, Mikhailidis DP, Wierzbicki AS. Epicardial fat and vascular risk: a narrative review. Curr Opin Cardiol. 2013 Jul;28(4):458-63

103. Ewang-Emukowhate M, Wierzbicki AS. Lipid-lowering agents. J Cardiovasc Pharmacol Ther. 2013 Sep;18(5):401-11

104. Barnett J, Viljoen A, Wierzbicki AS. The need for combination drug therapies in patients with complex dyslipidemia. Curr Cardiol Rep. 2013 Aug;15(8):391.

105. Athyros VG, Wierzbicki AS. Statin-fibrate combination therapy is safe and effective in normalizinglipid profile and in keeping cardiovascular event rates low. Curr Med Res Opin. 2014 Jan; 30(1):57-8

106. Katsiki N, Athyros VG, Karagiannis A, Wierzbicki AS, Mikhailidis DP. Should we expand the concept of coronary heart disease equivalents? Curr Opin Cardiol. 2014 Jul;29(4):389-95

107. Ewang-Emukowhate M, Perera D, Wierzbicki AS. Dyslipidaemia related to insulin resistance andcardiovascular disease in South Asian and West African populations. Curr Pharm Des. 2014;20(40):6270-5

108. Wierzbicki AS, Viljoen A. Fibrates and niacin: is there a place for them in clinical practice? Expert Opin Pharmacother. 2014 Dec;15(18):2673-80

109. Katsiki N, Wierzbicki AS, Mikhailidis DP. Erectile dysfunction and coronary heart disease. Curr Opin Cardiol. 2015 Jul;30(4):416-21.

110. Qureshi N, Minhas R, Wierzbicki AS. Prioritizing health outcomes in a limited world: writing lipid guidelines. Curr Opin Lipidol. 2015 Jun;26(3):188-94.

111. Viljoen A, Wierzbicki AS. Improving the odds: ezetimibe and cardiovascular disease. Int J Clin Pract. 2015 Apr;69(4):390-5.

112. Wierzbicki AS, Perera D, Ewang-Emukowhate M. Dyslipidaemia: what's around the corner? Clin Med (Lond). 2014 Dec;14 Suppl 6:s41-4.

113. Sijbrands EJ, Nieman K, Budoff MJ; FH CTA Consortium. Cardiac computed tomography imaging in familial hypercholesterolaemia: implications for therapy and clinical trials. Curr Opin Lipidol. 2015 Dec;26(6):586-92.

114. Wierzbicki AS, Watts GF. The hinterland of familial hypercholesterolaemia: what do we not know?Curr Opin Lipidol. 2015 Dec;26(6):475-83.

115. Hughes DP, Viljoen A, Wierzbicki AS. Familial Hypercholesterolaemia in the Era of Genetic Testing. Curr Cardiol Rep. 2016 May;18(5):42.

116. Wierzbicki AS, Grant P. Drugs for hypercholesterolaemia - from statins to pro-protein convertase subtilisin kexin 9 (PCSK9) inhibition. Clin Med (Lond). 2016 Aug;16(4):353-7.

117. Maghsoodi N, Wierzbicki AS. Statin myopathy: over-rated and under-treated? Curr Opin Cardiol. 2016 Jul;31(4):417-25.

118. Wierzbicki AS, Viljoen A. Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia. Expert Opin Biol Ther. 2016 Sep;16(9):1125-34.

119. Rifai N, Young IS, Nordestgaard BG, Wierzbicki AS, Vesper H, Mora S, Stone NJ, Genest J, Miller G. Non-fasting Sample for the Determination of Routine Lipid Profile: Is It an Idea Whose Time Has Come? Clin Chem. 2016 Mar;62(3):428-35.

120. Min SS, Wierzbicki AS. Radiotherapy, chemotherapy and atherosclerosis. Curr Opin Cardiol. 2017 Jul;32(4):441-447.

121. Ramachandran R, Wierzbicki AS. Statins, Muscle Disease and Mitochondria. J Clin Med. 2017 Jul 25;6(8). pii: E75.

122. Wierzbicki AS. The challenges of proprotein convertase subtilisin-kexin-9 inhibitors for lipid guidelines and models of care. Curr Opin Lipidol. 2017 Dec 28(6):470-476

123. Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Familial hypercholesterolaemia. Nat Rev Dis Primers. 2017 Dec 7;3:17093

124. Wierzbicki AS, Reynolds TM, Viljoen A. An update on trials of novel lipid-lowering drugs. Curr Opin Cardiol. 2018 Jul;33(4):416-422

125. Chaudhry R, Viljoen A, Wierzbicki AS. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome. Expert Rev Clin Pharmacol. 2018 Jun;11(6):589-598



126. Wierzbicki AS. Further options for treating lipids in people with diabetes: targeting LDL-cholesterol and beyond. Diabet Med. 2018 May 15. doi: 10.1111/dme.13667

127.

Editorials:

1. Wierzbicki AS. Statins: current research and clinical benefits; Br J Cardiol 1998; 45 suppl 1: S6

2. Wierzbicki AS. Editorial. Does diet have a role in the treatment of hyperlipidaemia? Int J Clin Practice 2000; 54 : 72-3

3. Wierzbicki AS. Editorial: The implications of the National Service Framework for coronary heart disease. J Roy Soc Health 2000; 120 : 143-145

4. Wierzbicki AS. Editorial. Is a statin a statin? Int J Clin Practice 2001; 55 : 78-80

5. Mikhailidis DP, Wierzbicki AS. Editorial. Attaining United States and European guideline LDL-C levels with simvastatin in patients with coronary heart disease (the GOALLS study). Curr Med Res Opinion 2000; 16 : 205-207

6. Wierzbicki AS. Editorial. Synthetic statins: more data on newer lipid-lowering agents. Curr Med Res Opinion 2001; 17: 74-77

7. Wierzbicki AS. Editorial: Statins: myalgia and myositis. Brit J Cardiol 2002; 9 : 193-194

8. Mikhailidis DP, Wierzbicki AS. Editorial: The GREek Atorvastatin and Coronary-heart disease Evaluation (GREACE) study. Curr Med Res Opinion 2002; 18 : 215-219

9. Wierzbicki AS. Ezetimibe. A viewpoint Am J Cardiovasc Drugs 2003; 3: 77-78

10. Wierzbicki AS. Editorial : Imidazoles as cholesterol-lowering agents. Int J Cardiol 2003; 90: 141-146

11. Wierzbicki AS. Editorial: Aggressive lipid-lowering in high-risk patients: warranted or excessive? IntJ Clin Pract 2003; 57 : 256-257

12. Wierzbicki AS. Editorial. Treatment-to –target for lipids in primary care. Int J Clin Pract 2003; 57 : 459-461

13. Wierzbicki AS. Editorial: Ezetimibe: A new addition to lipid-lowering therapy. Int J Clin Pract 2003; 57 : 653-655

14. Wierzbicki AS. Editorial. Atorvastatin and rosuvastatin reduce LDL-C more than other statins. Evidence based Cardiovascular Medicine 2003; 1-2

15. Foxton J, Wierzbicki AS, Reckless JPD. HEART-UK: hyperlipidaemia and the challenges ahead. Brit J Cardiol 2003; 10 ; 416-417

16. Twomey P, Wierzbicki AS, Reynolds TM. The casino of life: markets, mathematics and medicine. JClin Path 2004; 57 : 243-244

17. Wierzbicki AS. Editorial. Targeting multiple pathways in cholesterol management. Brit J Cardiol 2003; 11 supplement 3 : S13-S15

18. Wierzbicki AS. Editorial Genetics & Molecular Biology: Genetic epidemiology. Curr Opin Lipidol 2004; 15 : 699-701

19. Twomey PJ, Wierzbicki AS, Reynolds TM. Chemical pathology and the new contract for GPs. J Clin Pathol 2004; 57 :1022-1024

20. Wierzbicki AS. Statins and hypertension. J Hum Hypertens 2006; 20: 554-556

21. Wierzbicki AS. Lipid-lowering, statin and cancer. Int J Clin Pract 2006; 60: 1021-1027

22. Wierzbicki AS. Low HDL-C; Common and under-treated, but which drug to use?

Int J Clin Pract. 2006; 60: 1149-1153

23. Wierzbicki AS, Ganotakis EM, Mikhailidis DP. Shape of Nations survey and attitudes to cardiometabolic risk. Curr Med Res Opin 2007; 23 ; 25-28

24. Wierzbicki AS. Proprotein convertase subtilisin/kexin type 9, its variants and regulation of low-density lipoprotein cholesterol. Curr Opin Lipidol 2007: 18 : 227-229

25. Wierzbicki AS. Targets--who needs them? Success with statin therapies. Int J Clin Pract. 2007 Aug;61(8):1239-42

26. Kakafika AI, Mikhailidis DP, Wierzbicki AS, Karagiannis A, Athyros VG. PCI and stable coronary heart disease--COURAGE to change our minds? Curr Vasc Pharmacol. 2007 Jul;5(3):173-4

27. Wierzbicki AS.Raising HDL-C: back to the future? Int J Clin Pract. 2007 Jul;61(7):1069-71

28. Wierzbicki AS. Voodoo medicine: cardiovascular trials jinxed in New Orleans. Diab Vasc Dis Res



2007; in press

29. Wierzbicki AS. How aggressively should cholesterol targets be pursued? Brit J Hosp Med 2007 ; 68: 232-233

30. Wierzbicki AS. Primary and secondary prevention in obesity. Int J Clin Pract. 2007 Sep;61(9):1431-4

31. Wierzbicki AS. Quality as well as quantity? Beyond low-density lipoprotein-cholesterol - the role of particle size. Int J Clin Pract. 2007 Nov;61(11):1780-2

32. Paraskevas KI, Wierzbicki AS, Mikhailidis DP.METEOR: aiming at the stars for asymptomatic carotid artery atherosclerosis? Int J Clin Pract. 2007 Aug;61(8):1242-6

33. Kakafica AI, Mikhailidis DP, Wierzbicki AS, Karagiannis A, Athyros VG. PCI and stable coronary heart disease – COURAGE to change our minds? Vasc Dis Prev 2007; 4 : in press

34. Wierzbicki AS. Targets-who needs them? Success with statin therapies. Int J Clin Pract. 2007 Aug; 61(8):1239-42

35. Wierzbicki AS. Primary and secondary prevention in Obesity. Int J Clin Pract 2007; 61 : in press

36. Wierzbicki AS. Intervening on HDL-C: is it possible? Does it work? Int J Clin Pract. 2007 Nov; 61(11):1782-6

37. Viljoen A, Wierzbicki AS.Enhanced LDL-C reduction: lower is better. Does it matter how? Int J Clin Pract. 2008 Apr; 62(4):518-20

38. Wierzbicki AS. Lipoproteins: from A to B and maybe C-III. Int J Clin Pract. 2008 May; 62(5):674-6

39. Wierzbicki AS. Shielding the population from the metabolic syndrome? There is one born every minute. Int J Clin Pract 2008; 62 (8) : 1131-1132

40. Wierzbicki AS. Risk factors & cardiovascular disease. Summaries of ten seminal papers. DialogueCardiovasc Med 2008; 13 (2) : 131-143

41. Athyros VG, Kakafika AI, Wierzbicki AS, Karagiannis A, Mikhailidis DP. Targeting triglycerides in secondary prevention: should we bother? Int J Clin Pract 2009; 63 ; 15-19

42. Wierzbicki AS. Storms, tea cups and the adverse effects of statins. Int J Clin Pract. 2009 Sep;63(9):1268-7

43. Wierzbicki AS. Hot and bothered: C-reactive protein, inflammation and atherosclerosis. Int J Clin Pract. 2009 Nov; 63(11):1550-3

44. Wierzbicki AS, Peters BS. Putting protection first: vascular risk assessment in atypical populations.Int J Clin Pract. 2010 May;64(6):664-6

45. Wierzbicki AS. Practice makes perfect: reflections on a primary care treatment-to-target study. Int JClin Pract. 2010 Jul; 64(8):1006-8

46. Wierzbicki AS, Minhas R. The poly-pill: does it work and is chronic therapy acceptable? Int J Clin Pract. 2010 Aug; 64(9):1171-3

47. Wierzbicki AS. Comparing apples and pears: assessment of lipid-lowering therapies differentiated by side effects. Int J Clin Pract. 2010 Sep; 64(10):1324-6.

48. Wierzbicki AS. Cardiovascular screening: which populations, what measures of risk? Int J Clin Pract. 2011 Jan;65(1):3-5

49. Wierzbicki AS. Statin wars: efficacy vs. cost. Int J Clin Pract. 2011 Feb;65(2):108-11

50. Wierzbicki AS. Niacin: the only vitamin that reduces cardiovascular events. Int J Clin Pract. 2011 Apr;65(4):379-85

51. Wierzbicki AS, Hubbard JG, Botha AJ. A renaissance for cardio-metabolic surgery: better outcomes and lower costs? Int J Clin Pract. 2011 Jul;65(7):728-32

52. Wierzbicki AS. HDL: who needs it? Int J Clin Pract. 2011 Nov;65(11):1111-3

53. Wierzbicki AS. The ezetimibe Jonah: the trials and tribulations of an unlucky drug. Int J Clin Pract. 2011 Dec;65(12):1207-8

54. Wierzbicki AS Lumping and splitting in cardiovascular risk. Int J Clin Pract. 2012 Jun;66(6):522-4

55. Wierzbicki AS. Doubling up: maximising statin therapy as opposed to adding other drugs for cardiovascular disease prevention. Int J Clin Pract. 2013 May;67(5):391-3.

56. Wierzbicki AS, Reynolds TM. Secondary tests for stratification of risk for atherosclerosis. Curr MedRes Opin. 2013 Jun;29(6):597-9

57. Wierzbicki AS. Sugar, sugar. Int J Clin Pract. 2013 Apr;67(4):294-6



58. Wierzbicki AS. Dyslipidaemia: Failure to THRIVE: the end for niacin? Nat Rev Cardiol. 2013 May;10(5):246-7

59. Wierzbicki AS. All at sea: new lipid-lowering drug trials continue to disappoint. Int J Clin Pract. 2013 Jul;67(7):595-8

60. Wierzbicki AS, Ferro A. Lower, faster, better: the delusions of surrogate markers in hypertension. Int J Clin Pract. 2013 Sep;67(9):822-4

61. Wierzbicki AS. Moving the goalposts - towards cardiovascular prevention. Int J Clin Pract. 2016 Jun;70(6):429-31.

62. Wierzbicki AS. Mind the gap - surviving in the modern world. Int J Clin Pract. 2016 Jul;70(7):517-9.

63. Wierzbicki AS. Sensible economies: Demand management in blood science laboratories. Int J Clin Pract. 2017 Mar;71(3-4).

Other articles:

1. Wierzbicki AS. Academic Medicine. Not so funny an old game. BMA News Review 1998 (2)

2. Wierzbicki AS. Top 100: Hyperlipidaemia ; GP Medicine; April 10 1998; 62-64

3. Wierzbicki AS. W(h)ither academic pathology? ACP News Autumn 1998; 12-13

4. Wierzbicki AS. Hyperlipidaemia. National Association of Fundholding Practices Yearbook 1998 pp121-8

5. Wierzbicki AS. Cardiology: the cutting edge: When should statins be prescribed? Update (7 October 1998) 476-490

6. Wierzbicki AS. AVERTing angioplasties: are statins better than procedures? Cardiology News 1999; 2 (6): 6-7

7. Wierzbicki AS. Managing hyperlipidaemia. Postgraduate Doctor 1999; 22 : 9

8. Wierzbicki AS. Managing hyperlipidaemia. Cardiovascular Disease in Practice 1999; 1.3 : 27

9. Wierzbicki AS. New developments in hyperlipidaemia. Cardiology Update 1999; 2 (4) 1-2

10. Wierzbicki AS. Managing hyperlipidaemia. Cardiovascular Disease in Practice 1999; 1: 27

11. Wierzbicki AS. Is chemical pathology a scientific speciality? ACB News 2000; (441) 26

12. Wierzbicki AS. Statins and atheroma: new actions, novel controversies. Brit J Cardiol 2000; 7 suppl 3: S4-5

13. Wierzbicki AS. Top 100; Hyperlipidaemia . General Practitioner Sep 22 2000; 48-49

14. Wierzbicki AS. New developments in atherosclerosis. ACP Handbook 2002; 31-32

15. Wierzbicki AS. P45 to A45- a natural move for academic pathologists. ACP News Summer 2002; 11-13

16. Wierzbicki AS. What if statin treatment fails to reach LDL targets in atherosclerosis? Capital Doctor2002; November (issue 17) : 25-26

17. Wierzbicki AS. The new consultant contract and pathology. ACP News Autumn 2002; 32-34

18. Wierzbicki AS. Rationale governing the choice of lipid-lowering drugs. J. Assoc Primary Care Groups & Trusts. Autumn 2002; 38-43

19. Wierzbicki AS. Teaching pathology. ACP News Autumn 2003; 15-17

20. Wierzbicki AS. The commodity of diagnosis tayloring the NHS. ACP News Summer 2004; 35-37

21. Wierzbicki AS. Raising HDL. Capital Doctor 2004 August (issue 35): 18-20

22. Wierzbicki AS. Hyperlipidaemia. Independent Nurse (27 March 2006) 19-20

23. Wierzbicki AS, Lloyd MD. Dr Brian Gibberd (1931-2006): a pioneering clinician in Refsum's disease. Biochem Soc Trans. 2007 Nov;35(Pt 5):862-4

24. Minhas R, Patel KCR, Wierzbicki AS. The UK needs an Institute of Medicine. Brit Med J 2008; 337: 637

25. Minhas R, Wendt C, Wierzbicki AS. Is healthcare in the United States too big to fail? Int J Clin Pract 2008; 62(12) : 1827-1830

26. Minhas R, Wierzbicki AS. Truthiness and quality improvement. Int J Clin Pract 2008; 63(6) : 839-840

27. Moon JC, Flett AS, Godman BB, Grosso AM, Wierzbicki AS. Getting better value from the NHS drug budget. BMJ. 2010 Dec 17;341:c6449

28.



Book reviews

1. Wierzbicki AS. Book review: Handbook of Lipoprotein Testing. Ann Clin Biochem 1999

2. Wierzbicki AS. Book review: Methods in Lipid Research: Clin Chem Lab Med 2000; 37

3. Wierzbicki AS. Book Review: Fatty Acids and Inflammatory skin diseases. J Clin Path 2000

4. Wierzbicki AS. Book Review: Lipids and cardiovascular disease. Brit J Cardiol 2003; 10: 140

5. Wierzbicki AS. Book review: The year in hyperlipidaemia 2003; Evidence –Based Cardiovascular Medicine ; 2004 ; 8 : 195

6. WierzbickiAS. Book review: A guide to laboratory investigations. Curr Med Res Opin 2004; 20: 1166

7. Wierzbicki AS. Book review: Molecular mechanisms of atherosclerosis. Int J Clin Pract. 2005; 59: 1120

8.

Other Media

1. Wierzbicki AS. A difficult case of hyperlipidaemia. Interactive CD-ROM

(sponsored by Novartis Pharmaceuticals)

Chapters

1. Gibberd FB, Wierzbicki AS. Heredopathia atactica polyneuritiformis in Handbook of Ataxia Disorders. Ed: Klockgether T. Marcel Decker Basel 2000 pp235-256

2. Lloyd MD, Mukherji M, Kershaw NJ, Chien W, Wierzbicki AS, Schofield CJ. Role of phytanoyl-CoA 2-hydroxylase in phytanic acid degradation. In. Peroxisomal Disorders and regulation of genes. Eds. Roels F, Baes M, De Bie S. Kluwer/Plenum 2003 ISBN 0-306-48174-X Adv Exp Med Biol. 2003; 544: 303-4

3. Van den Brink DM, Brites P, Haasjes J, Wierzbicki AS, Mitchell J, Lambert-Hamill M, de Belleroche J, Jansen GA, Waterham HR, Wanders RJ. Identification of PEX7 as the second gene involved in Refsum disease. In. Peroxisomal Disorders and regulation of genes. Eds. Roels F, Baes M, De Bie S. Kluwer/Plenum 2003 ISBN 0-306-48174-X

Adv Exp Med Biol. 2003; 544: 69-70

4. Wierzbicki AS. Lipid-lowering in the Elderly. In. Practical Handbook of Geriatric Prescribing. Eds: Jackson S, Jensen J, Mangoni A. John Wiley UK 28/12/2007 ISBN-10-0470024283

5. Wierzbicki AS. Triple therapy in the treatment of hyperlipidaemia. Case 32. In Case Studies in Lipid Management. Ed; Betteridge DJ. Informa healthcare 2008 pp 165-170. ISBN-10-184184472

6. Wierzbicki AS. Prevention. In Acute Coronary Syndromes. Oxford Cardiology Library. Ed Jackson G. Oxford University Press pp 15-26 2008 ISBN 978-0-19-954349-6

7. Wierzbicki AS, Redwood S. Cardiac complication and management. In The evidence base for Diabetes Care. Eds Herman WH, Kinmouth AL, Wareham NJ, Williams R. Wiley Blackwell 2nd edition2010. pp 355-77 ISBN 978-047-003-27498

8. Viljoen A, Wierzbicki AS. How do we diagnose hypertriglyceridaemia in clinical practice and what are the consequences for treatment? In: Evidence based textbook of Diabetes 4th edition Ed Visser MN, Kastelein JJP. Stroes ES. 2010 TFM Press Harley, Shropshire, UK ISBN 978-1-903378-71-7 pp 91-111

9. Viljoen A, Wierzbicki AS. Cardiovascular risk factors II; dyslipidaemia. Textbook of Diabetes. Eds: Holt RIG, Cockram CS, Flyvberg A; Goldstein BJ. OUP Oxford UK 2011; ISBN 978-1-4051-9181-4 pp672-683

10. Wierzbicki AS. Refsum Disease. In: Encyclopaedia of Movement Disorders. Eds: Kompoliti K, Verhagen L. Elsevier (02-2010) ISBN 978-0-12-374101-1

11. Wierzbicki AS. Adult neurological disorders of peroxisomes. In: Oxford Textbook of Medicine , Eds Warrell DA, Cox TM, Firth JD. OUP Oxford; 5th edition (13 May 2010) ISBN 978-0199204854

12. Viljoen A, Wierzbicki AS. Lipid Management. In Principles and Practice of Geriatric Medicine, 5th Edition. Ed Sinclair AJ, Morley JE, Vellas B. 2012 John Wiley & Sons, Oxford UK

13. Wierzbicki AS. Combination therapy for the management of hyperlipidaemia. OCL Hyperlipidaemia. Editor: Betteridge DJ. OUP Oxford UK 2012 ISBN 978-0-19-954350-2 pp103-110

14. Viljoen A, Wierzbicki AS. Lipid Management . Chapter 38 pp 449-460 In: Pathy's Principles and Practice of Geriatric Medicine, 5th Edition 2012 Eds: Sinclair AJ, Morley JE, Vellas B. Wiley-Blackwell, Oxford. ISBN: 978-0-470-68393-4.

15. Wierzbicki AS, Viljoen A. Hypertension. Chapter 40 pp 471-482 In: Pathy’s Principles and Practice



of Geriatric Medicine, 5th Edition. 2012 Eds: Sinclair AJ, Morley JE, Vellas B. Wiley-Blackwell, Oxford UK ISBN: 978-0-470-68393-4.

16. Wierzbicki AS, Viljoen A. Hypertension. In Cardiovascular Disease and Health in the Older Patient.Eds Stott DJ, Lowe GDO. 5th Edition 2013 pp 44-67. ISBN 978-0-470-97372

17. Viljoen A, Wierzbicki AS. Hyperlipidaemia. In Cardiovascular Disease and Health in the Older Patient. Eds Stott DJ, Lowe GDO. 5th Edition 2013 pp 68-89. ISBN 978-0-470-97372

18. Viljoen A, Joshi S, Wierzbicki AS. Diabetic dyslipidaemia and risk of cardiovascular disease. Textbook of Diabetes. Eds: Holt RIG, Cockram CS, Flyvberg A; Goldstein BJ. OUP Oxford UK 2017; pp 643-653 ISBN 978-1-189-12027

19. Meek C, Clarke RE, Wierzbicki AS. Metabolic Medicine. Medicine for MRCP. Oxford University Press 2019- in press

20. Wierzbicki AS, Ramachandran R. Lipids and Inherited Metabolic Disease. Kumar & Clarke’s Clinical Medicine- in press

Books

1. Crook MA. Minhas R, Reynolds TM, Twomey PJ, Viljoen A, Wierzbicki AS. Problem Solving in Cardiovascular Risk. Clinical Publishing (Oxford) 2011. ISBN 13-978-1-904392-98-9

Papers:

1. Harkiss GD, Wierzbicki AS. Immunoglobulin isotypes in immune complexes in cardiac allograft recipients. J Clin Lab Immunol 1984; 13 : 155-160

2. Wierzbicki AS, Tozer RG, Lolin Y, Lascelles PT, Thomas S, Hjelm M. Screening for metabolic disorders in adult neurological patients. Lancet 1988; i : 1102

3. Barnicoat MJ, Wierzbicki AS, Norman PM. Cerebral nocardiosis in immunocompromised patients: 5 cases. Quart J Med 1989; 62 : 301-310

4. Wierzbicki AS, Cousins DM. Autoimmunity: a risk factor for allosensitisation to blood products. Brit Med J 1989; 298 : 65-6

5. Lolin Y, Razis PA, O'Gorman P, Hjelm M, Wierzbicki AS. Transient nephrotic syndrome after anaesthesia resulting from a familial cryofibrinogen precipitating at 35oc. J Med Genet 1989; 26 : 631-636

6. Gilois CR, Stone J, Lai AP, Wierzbicki AS. Effect of haemolysate preparation on measurement of red cell folate by a radio-isotopic method. J Clin Pathol 1990; 43 : 160-162

7. Nijhawan R, Wierzbicki AS, Tozer R, Lascelles PT, Patsalos PN. Antiepileptic drugs, hepatic enzyme induction and raised serum alkaline phosphatase isoenzymes. Int J Clin Pharm Res 1990; 10: 319-323

8. Lai AP, Wierzbicki AS, Norman PM. Immunocytological detection of primary cerebral non-Hodgkin'slymphoma in the cerebrospinal fluid. J Clin Pathol 1991; 44 : 251-253

9. Wierzbicki AS, Gibbs J, Lidov HGV, Lolin Y, Thomas PK. Cerebral neoplastic angioendotheleosis associated with hypercalcaemia. Postgrad Med J 1991; 67 : 571-574

10. Gilois C, Wierzbicki AS, Hirani N, Norman PM, Ponsford S, Alani M, Jones SJ, Kriss AJ. The haematological and electrophysiological effects of cobalamin deficiency secondary to vegetarian diets.Annals New York Acad Sci 1992; 669 : 345-349

11. Wierzbicki AS, Beeson DMW, Lang B, Newsom-Davis J. Tissue distribution of the 2- subunit gene of the voltage gated calcium channel in rodent tissues and cell lines. Annals New York Acad Sci 1993; 681 : 422-424

12. Wierzbicki AS, Luxton R, McLean BN, Gilois C, Norman PM, Thompson EJ. Hairy leukaemic cell influx into the cerebrospinal fluid following encephalomeningitis. Postgrad Med J 1993; 69: 651-653

13. Wierzbicki AS, Beeson DMW, Lang B, Newsom-Davis J. Tissue specific expression of putative domains of the mouse neuronal alpha-2 and delta genes of the voltage-gated calcium channel in rodent tissues and cell lines. Ann New York Acad Sci 1993; 707 : 472-476

14. Wierzbicki AS, Evans K, Patel N, Lascelles PT. 64Copper metabolism in non-Wilsonian low copper movement disorder. J Neurol Sci 1993; 119 : 85-90

15. Wierzbicki AS, Nimmo L, Feher MD, Cox A, Foxton J, Lant AF. Association of the angiotensin converting enzyme DD genotype with hypertension in diabetes. J Hum Hypertens 1995; 9 : 671-3

16. Hardman TC, Croft P, Barlow R, Wierzbicki AS, Feher MD, Lant AF. Ethnic origin and hypertension associated alterations in sodium-lithium countertransport (SLC) kinetics. J Hum Hypertens 1995; 9: 687-689

17. Hardman TC, Wierzbicki AS, Cox A, Feher MD, Lant AF. Angiotensin converting enzyme (ACE)



gene genotype and the erythrocyte sodium-lithium countertransporter (SLC) phenotype in patients with hypertension. J Hum Hypertens 1996; 10 : 429-430

18. Jefferson A, Reynolds TM, Wierzbicki AS. Patients with recurrent renal stones have a physico-chemically altered urinary Tamm-Horsfall protein. Ann Clin Biochem 1996; 33 : 450-5

19. Chowienczyk PJ, Watts GF, Wierzbicki AS, Cockroft JR, Brett SE, Ritter JM. Preserved endothelial function in patients with severe hypertriglyceridaemia and low functional lipoprotein lipase activity. J Am Coll Cardiol 1997; 29 : 964-968

20. Cummings MH, Christ E, Umpleby AM, Albany E, Wierzbicki AS, Lumb PJ, Sonksen PH, Russell-Jones D. Abnormalities of very low density lipoprotein apolipoprotein B-100 metabolism contribute to the dyslipidaemia of adult growth hormone deficiency. J Clin Endocrinol Metab 1997; 82 : 2010-2013

21. Wierzbicki AS, Nimmo L, Lambert M. Ambiguities in angiotensin-converting enzyme genotyping: acomparison of three methods. J Hum Hypertens 1997; 11 : 467-468

22. Wierzbicki AS, Lumb PJ, Cheung J, Crook MA. Experience with simvastatin-fenofibrate combination therapy compared to simvastatin-cholestyramine therapy for familial hypercholesterolaemia. Quart J Med 1997; 90 : 631-634

23. Johnson JD, Lumb PJ, Wierzbicki AS. Hyperlipidaemia in association with benign paraproteinaemia. Ann Clin Biochem 1997; 34 : 697-699

24. Wierzbicki AS, Ball SG, Singh NKR. Profound hyponatraemia following an idiosyncratic reaction todiuretics. Int J Clin Practice 1998; 52 : 278-280

25. Wierzbicki AS. Sankaralingam A, Lumb P, Hardman TC, Sidey MC, Gibberd FB. Influence of plasma phytanic acid levels in Refsum’s disease on the behaviour of the erythrocyte membrane sodium-lithium countertransporter. Eur J Clin Invest 1998; 28 : 334-338

26. Wierzbicki AS, Lumb PJ, Semra YK, Crook MA. High-dose atorvastatin therapy compared with traditional therapeutic regimes in severe heterozygous familial hypercholesterolaemia. Quart J Med 1998; 91: 291-294

27. Wierzbicki AS, Lumb PJ, Semra YK, Crook MA. Effect of atorvastatin on plasma fibrinogen. Lancet 1998; 351 : 591-592

28. Wierzbicki AS. Sankaralingam A, Lumb P, Hardman TC, Sidey MC, Gibberd FB. Transport of phytanic acid on lipoproteins in Refsum’s Disease. J Inherited Metabolic Dis 1999; 22 : 29-36

29. Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999; 142 :105-112

30. Christ ER, Cummings MH, Albany E, Umpleby AM, Lumb PJ, Wierzbicki AS, Naoumova RP, Boroujerdi MA, Sonksen PH, Russell-Jones DL. Effects of growth hormone replacement therapy on VLDL apolipoprotein B-100 kinetics in patients with adult growth hormone deficiency: a stable isotope study. J Clin Endocrinol Metab 1999; 84 : 307-316

31. Wierzbicki AS, Lumb PJ, Semra YK, Chik G, Christ ER, Crook MA. Efficacy of atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias. Quart J Med 1999; 92 : 387-394

32. Wierzbicki AS, Lumb PJ, Chik G, Crook MA. Comparison of therapy with simvastatin 80mg or atorvastatin 80mg in patients with familial hypercholesterolaemia. Int J Clin Pract 1999; 53 : 609-611

33. Hardman TC, Dubrey SW, Soni S, Clifford R, Chalkley S, Wierzbicki AS. Urinary retinol-binding protein (RBP) excretion and erythrocyte sodium-lithium countertransport (SLC) activity in a cohort of healthy normotensive subjects. J Hum Hypertens 1999; 13 : 871-873

34. Lloyd G, McGing E, Cooper A, Patel N, Lumb PJ, Wierzbicki AS, Jackson G. A randomised placebo controlled trial of the effects of tibolone on blood pressure and lipids in hypertensive women. JHum Hypertens 2000; 14 : 99-104

35. Wierzbicki AS, Reynolds TM, Gill K, Alg S, Crook MA. A comparison of algorithms for initiation of lipid lowering therapy in primary prevention of coronary heart disease. J Cardiovasc Risk 2000; 7 : 63-73

36. Wierzbicki AS, Mitchell J, Lambert-Hammill M, Hancock M, Greenwood J, Sidey MC, de Belleroche J, Gibberd FB. Identification of genetic heterogeneity in Refsum’s disease. Eur J Hum Genet 2000; 8: 649-651

37. Algaratnam D, Wierzbicki AS, Swaminathan R, Turner C, Wickramasinghe SN. Serum homocysteine, folate and thermolabile variant of MTHFR in healthy Sri Lankans living in London. Atherosclerosis 2000; 149: 221-222

38. Wierzbicki AS, Lumb PJ, Chik G, Crook MA. High-density lipoprotein cholesterol and triglyceride response with Simvastatin vs. Atorvastatin in familial hypercholesterolemia. Am J Cardiol 2000; 86 :



547-549

39. Wierzbicki AS, Hardman TC, Cheung J, Lambert-Hammill M, Patel S, Morrish Z, Lumb, PJ, Lant AF. Effects of lipids in patients with familial hypercholesterolaemia on the kinetics of the sodium-lithiumcountertransporter. J Hum Hypertens 2000; 14 :561-565

40. Wierzbicki AS, Lambert-Hammill M, Lumb PJ, Crook MA. Renin-angiotensin system polymorphisms and coronary events in familial hypercholesterolemia. Hypertension 2000; 36 : 808-812

41. Wierzbicki AS, Lambert-Hammill M, Junadi E, Lumb PJ, Crook MA. Differing relationships of methylene tetrahydrofolate reductase genotypes with cardiovascular risk in familial and polygenic hypercholesterolaemia. J Cardiovasc Risk 2000; 7 : 431-434

42. Wierzbicki AS, Hardman TC, Cheung J, Patel M, Smallberger S, Lumb PJ, Lant AF. Relation between sodium-lithium countertransport and hypertriglyceridemia in type V hyperlipidemia. Am J Hypertens 2001; 14 : 32-37

43. Wierzbicki AS, Lumb PJ, Chik G, Crook MA. Fibrinogen response with Simvastatin vs. Atorvastatin in familial hypercholesterolemia. Am J Cardiol 2001; 87 : 338-340

44. Mangoni AA, Ouldred E, Swift CG, Jackson SH, Draper RP, Sherwood RA, Lambert-Hammill M, Wierzbicki AS. Beneficial effects of folic acid in patients with cardiovascular disease. J Am Geriatric Soc 2001; 49: 1003-1004

45. Mukherji M, Kershaw NJ, MacKinnon CH, Clifton IJ, Wierzbicki AS, Schofield CJ, Lloyd MD. ‘Chemical co-substrate rescue’ of phytanoyl-CoA 2-hydroxylase mutants causing Refsum’s disease. Chem Commun 2001; 11: 972-973

46. Wierzbicki AS, Watts GF, Lynas J, Winder AF, Wray R. Very-low density lipoprotein apolipoprotein B-100 turnover in glycogen storage disease type 1a (von Gierke’s disease). J Inher Metab Dis 2001; 24 :527-534

47. Kershaw NJ, Mukherji M, MacKinnon CH, Claridge TDW, Odell B, Wierzbicki AS, Lloyd MD, Schofield CJ. Studies on phytanoyl-CoA 2-hydroxylase and synthesis of phytanoyl-Coenzyme A. Bioorg Med Chem Lett 2001; 11 : 2545-2548

48. Mukherji M, Chien W, Kershaw NJ, Clifton IJ, Schofield CJ, Wierzbicki AS, Lloyd MD. Structure-function analysis of phytanoyl-CoA 2-hydroxylase mutations causing Refsum’s ‘Disease’. Hum Mol Genet 2001; 10 : 1971-1982

49. Christ ER, Carroll PV, Albany E, Umpleby AM, Lumb PJ, Wierzbicki AS, Simpson HL, Sönksen PH, Russell-Jones DL. Normal VLDL metabolism despite altered lipoprotein composition in type 1 diabetes mellitus. Clin Endocrinol 2001; 55 ; 777-787

50. Wierzbicki AS, Lumb PJ, Chik G. Comparison of therapy with simvastatin 80mg and 120mg in patients with familial hypercholesterolaemia. Int J Clin Pract 2001; 55 : 673-675

51. Wierzbicki AS, Reynolds TM, Crook MA. Usefulness of orlisat in the treatment of severe hypertriglyceridemia. Am J Cardiol 2002 ; 89 : 229-230

52. Newman P, Bonello F, Wierzbicki AS, Lumb PJ, Savidge GF, Shearer MJ. The uptake of lipoprotein-borne phylloquinone (vitamin K1) by osteoblasts: role of heparan sulphate proteoglycans and apolipoprotein E. J Bone Mineral Res 2002; 17 : 426-433

53. Wierzbicki AS, Hardman TC, Cheung J, Lambert- Hammill M, Patel S, Morrish Z, Lumb PJ, Lant, AF. The apolipoprotein E2 allele modulates activity and maximal velocity of the sodium-lithium countertransporter. Am J Hypertens 2002; 15 : 633-637

54. Wierzbicki AS, Reynolds TM. Total research productivity in a pathology discipline. J Clin Pathol 2002; 55: 495-498

55. Christ ER, Carroll PV, Albany E, Umpleby AM, Lumb PJ, Wierzbicki AS, Sönksen PH, Russell-Jones DL. The effect of IGF-1 therapy on VLDL apolipoprotein B-100 metabolism in type 1 diabetes mellitus. Am J Physiol Endcrinol Metab 2002; 282 : E1154-E1162

56. Reynolds TM, Twomey P, Wierzbicki AS. Accuracy of cardiovascular risk estimation in patients without diabetes. J Cardiovasc Risk 2002; 9 : 183-190

57. Mukherji M, Kershaw NJ, Schofield CJ, Wierzbicki AS, Lloyd MD. Utilization of sterol carrier protein-2 by phytanoyl-CoA hydroxylase in the peroxisomal -oxidation of phytanic acid. Chemistry &Biology 2002; 9 : 597-605

58. Solomon H, Man JW, Wierzbicki AS, Jackson G. Relation of erectile dysfunction to angiographic coronary artery disease. Am J Cardiol 2003; 91 : 230-231

59. van den Brink DM, Waterham HR, Wierzbicki AS, Mitchell J, Lambert-Hammill M, de Belleroche J,Haasjes J, Jansen GA, Wanders RJA. Clinical heterogeneity in peroxin 7 (peroxisome targeting



signal-2 protein) disorders: a second locus for adult Refsum’s disease. Am J Hum Genet 2003; 72 : 471-477

60. Solomon H, Man J, Wierzbicki AS, O'Brien T, Jackson G. Erectile dysfunction: cardiovascular risk and the role of the cardiologist. Int J Clin Pract. 2003; 57 : 96-99

61. Wierzbicki AS, Mayne PD, Lloyd MD, Burston D, Mei G, Sidey MC, Feher MD, Gibberd FB. Metabolism of phytanic acid and 3-methyl-adipic acid excretion in patients with adult Refsum’s disease. J Lipid Res 2003; 44 : 1481-1488

62. Badawy O, Wierzbicki AS, Hilton R. Combination fibrate-statin therapy for the treatment of severe hypertriglyceridaemia in renal disease. Int J Clin Pract. 2003; 57: 249-251

63. Huxley RR, Hawkins MH, Humphries SE, Karpe F, Neil HAW for the Simon Broome Familial hyperlipidaemia Register Group and Scientific steering committee. Risk of fatal stroke in patients with treated familial hypercholesterolaemia. Stroke 2003; 34 : 22-27

64. Suryanarayanan S, Wierzbicki AS, Carr R, Ritter JM. Hypertriglyceridaemia and NK cell lymphoma. Int J Clin Pract 2003; 57: 921-923

65. Pantelidis P, Lambert-Hammill M, Wierzbicki AS. Simple Sequence-specific-Primer-PCR method to identify the three main apolipoprotein E haplotypes Clin Chem 2003; 49: 1945-1948

66. Bakri R, Wang J , Wierzbicki AS, Goldsmith DJA. Cerivastatin monotherapy-induced muscle weakness, rhabdomyolysis and acute renal failure. Int J Cardiol 2003; 91: 107-109

67. Neil HA, Huxley RR, Hawkins MM, Durrington PN, Betteridge DJ, Humphries SE; Simon Broome Familial Hyperlipidaemia Register Group and Scientific Steering Committee. Comparison of the risk offatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study. Atherosclerosis 2003; 170: 73-78

68. Bakri RS, Afzali B, Bharma-Ariza P, Lumb PJ, Dalton N, Turner CN, Wierzbicki AS, Crook MA, Goldsmith DJA. Raised plasma total sialic acid levels, are markers of cardiovascular disease in renal dialysis patients. J Nephrol 2003 ; 16 : 540-545

69. Nishtar S, Wierzbicki AS, Lumb PJ, Lambert-Hammill M, Turner CN, Crook MA, Mattu MA, Shahab S, Marber MS, Gill J. HDL-cholesterol and waist-hip ratio predict risk of coronary heart disease in Pakistan. Curr Med Res Opin 2004; 20: 55-62

70. Bakri RS, Afzali B, Bharma-Ariza P, Lumb PJ, Dalton N, Turner CN, Wierzbicki AS, Crook MA, Goldsmith DJA. Cardiovascular disease in renal allograft recipients is associated with elevated sialic acid or markers of inflammation. Clin Transplant 2004; 18 : 201-204Reynolds TM, Wierzbicki AS. Does activity in research correlate with visibility? J Clin Path 2004; 57 : 426-427

73. Gibberd FB, Wierzbicki AS, Feher MD. Smell testing: an additional tool for identification of adult Refsum's disease. J Neurol Neurosurg Psychiatr 2004; 75 : 1334-1336

74. Somner J, McLellan S, Cheung J, Mak YT, Frost ML, Knapp KM, Wierzbicki AS, Wheeler M, Fogelman I, Ralston SH, Hampson GN. Polymorphisms in the P450 c17 (17-hydroxylase/ 17,20-lyase) and P450 c19 (aromatase) genes: association with serum sex steroids concentrations and bone mineral density in post-menopausal women. J Clin Endocrinol Metab 2004; 89 : 344-351

75. Christ ER, Cummings MH, Jackson N, Stolinski M, Lumb PJ, Wierzbicki AS, Sönksen PH, Russell-Jones DL, Umpleby AM. Effects of growth hormone replacement therapy on LDL apolipoprotein B-100 kinetics in adult patients with growth hormone deficiency: A stable isotope study. J Clin Endocrinol Metab 2004; 89: 1801-1807

76. Lumb PJ, McMahon Z, Chik G, Wierzbicki AS. Effect of moxonidine on lipid subfractions in patients with hypertension. Int J Clin Pract 2004; 58: 465-468

77. Reynolds TM, Twomey PJ, Wierzbicki AS. Concordance evaluation of risk scores: implications for cardiovascular risk screening. Curr Med Res Opin 2004; 20 : 811-818

78. Wierzbicki AS, Chowienczyk PJ, Cockcroft JR, Brett SE, Watts GF, Jenkins BS, Ritter JM. Calculated cardiovascular risk and endothelial dysfunction; Clin Sci 2004; 107: 609-615

79. Lumb PJ, MacMahon Z, Chik G, Wierzbicki AS. Effect of moxonidine on lipid subfractions in patients with hypertension. Int J Clin Pract. 2004; 58 : 465-468

80. Marteau T, Senior V, Humphries SE, Bobrow M, Cranston T, Crook MA, Day L, Fernandez M, Horne R, Iversen A, Jackson Z, Lynas J, Middleton-Price H, Savine R, Sikorski J, Watson M, Weinman J, Wierzbicki AS, Wray R. Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: A randomized controlled trial. Am J Med Genet. 2004;128A :285-293

81. Chambers JB, Takeda S, Wang Z, Rimington H, Lambert-Hammill M, Shetty C, Wierzbicki AS. Determinants of left ventricular mass in aortic stenosis. J Heart Valve Dis 2004; 13 : 873-880



82. Senior V, Marteau TM, Weinman J, on behalf of the GRAFT study group. Self-reported adherenceto cholesterol lowering medication in patients with familial hypercholesterolaemia: the role of illness perceptions. Cardiovasc Drug Ther 2004; 18 : 475-481

83. Wierzbicki AS, Nishtar S, Lumb PJ, Lambert-Hammill M, Turner CN, Crook MA, Marber MS, Gill J.Metabolic syndrome and risk of coronary heart disease in a Pakistani cohort. Heart 2005; 91: 1003-1007

84. Wijeratne S, Wray R, Collinson PO, Wierzbicki AS. Hypertriglyceridaemia and malignancy. Int J Clin Pract 2005; 59: 233-235

85. Wierzbicki AS, Doherty E, Lumb PJ, Chik G, Crook MA. Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias. Curr Med Res Opin 2005; 21 : 333-338

86. Doherty E, Lumb PJ, Chik G, Wierzbicki AS. Ezetimibe-induced hyperlipidaemia. Int J Clin Pract Grand Rounds 2005; 59 (suppl 147); 3-5

87. Pearson ER, Pruhova S, Tack C, Johansen A, Castleden H, Lumb PJ, Wierzbicki AS, Clark PM, Lebl J, Pedersen O, Ellard S, Hansen T, Hattersley AT. Molecular genetics and phenotypic characteristics of MODY due to HNF-4α mutations in a large European collection. Diabetologia 2005; 48 : 878-885

88. Wierzbicki AS, Nishtar S, Lumb PJ, Lambert-Hammill M, Crook MA, Marber MS, Gill J. Impaired renal function and atherosclerosis in a Pakistani cohort. Curr Med Res Opin 2005; 21 : 1201-1207

89. Twomey PJ, Viljoen A, House IM, Reynolds TM, Wierzbicki AS. Relationship between Serum Copper, Ceruloplasmin, and Non-Ceruloplasmin-Bound Copper in Routine Clinical Practice. Clin Chem. 2005; 51: 1558-1559

90. Kumar J, Wierzbicki AS. Images in clinical medicine. Lipemia retinalis. New Engl J Med 2005; 353 : 823

91. Humphries SE, Cranston T, Allen M. Middleton-Price H, Fernandez MC, Senior V, Hawe E, Iversen A, Wray R, Crook MA, Wierzbicki AS. Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing. J Mol Med 2006; 84: 203-214

92. Solomon H, Man J, Samarasinghe YP, Rivas-Toro H, Lumb PJ, Feher MD, Wierzbicki AS, Jackson G. Erectile dysfunction and statin treatment in high cardiovascular risk patients. Int J Clin Pract 2006; 60 : 141-145

93. Solomon H, Wierzbicki AS, Lumb PJ, Lambert-Hammill M, Jackson G. Cardiovascular risk factors determine erectile and arterial function response to sildenafil. Am J Hypertens 2006; 19: 915-919

94. Dann AT, Kenyon AP, Wierzbicki AS, Seed PT, Poston L, Shennan AH, Tribe RM. Plasma lipid profiles of women with intrahepatic cholestasis of pregnancy and pruritus gravidarum. Obstet Gynecol 2006; 107 : 106-114

95. Wierzbicki AS, Solomon H, Lumb PJ, Lyttle K, Lambert-Hammill M, Jackson G. Asymmetric dimethyl-arginine levels correlate with cardiovascular risk factors in patients with erectile dysfunction. Atherosclerosis 2006; 185 : 421-425

96. Christ ER, Cummings MH, Stolinski M, Jackson N, Lumb PJ, Wierzbicki AS, Sönksen PH, Russell-Jones DL, Umpleby AM. LDL-apolipoprotein B100 Turnover in Hypopituitary Patients with Growth Hormone (GH)-Deficiency: a Stable Isotope Study. Eur J Endocrinol 2006; 154: 459-466

97. Twomey PJ, Viljoen A, House IM, Reynolds TM, Wierzbicki AS. Adjusting copper concentrations for caeruloplasmin levels. J Clin Path 2006; 59; 867-869

98. Roze S, Wierzbicki AS, Liens D, Renaudin C. Cost-effectiveness of adding prolonged-release nicotinic acid in statin-treated patients who achieve LDL cholesterol goals but remain at risk due to lowHDL cholesterol: a UK-based economic valuation. Brit J Cardiol 2006; 13; 411-418

99. Melikian N, Wheatcroft SB, Okechukwu OS, Murphy C, Chowienczyk PJ, Wierzbicki AS, Sanders TAB, Duncan ER, Shah AM, Kearney MT. Asymmetric dimethylarginine and reduced nitric oxide bioavailability in young black African men. Hypertension 2007; 49: 873-877

100. Chappuis B, Braun M, Stettler C, Allemann S, Diem P, Lumb PJ, Wierzbicki AS, James R, Christ ER.Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab Res Rev. 2007 Jul; 23(5) :392-9

101. Twomey PJ, Wierzbicki AS, Ivan M House IM, Viljoen A, Reynolds TM. Percentage non-caeruloplasmin bound copper. Clin Biochem 2007; 40 : 749-750

102. Wierzbicki AS, Nishtar S, Lumb PJ, Lambert-Hammill M, Crook MA, Marber MS, Gill J. Waist circumference, metabolic syndrome and coronary artery disease in a Pakistani cohort. Int J Cardiol.



2008; 128 (8) : 77-82

103. Gray J, Jaiyeola A, Whiting M, Modell M, Wierzbicki AS. Identifying patients with familial hypercholesterolaemia in primary care: an informatics-based approach in one primary care centre. Heart. 2008 Jun;94(6):754-8

104. Karim N, MacDonald D, Dolan AL, Fogelman I, Wierzbicki AS, Hampson G. The relationship between gonadotrophins, gonadal hormones and bone mass in men. Clin Endocrinol (Oxf). 2008 Jan;68(1):94-101

105. Twomey PJ, Reynolds TM, Wierzbicki AS, Viljoen A. The relationship between serum copper and ceruloplasmin in routine clinical practice. Int J Clin Pract. 2008 Mar;62(3):485-7

106. Twomey PJ, Viljoen A, Reynolds TM, Wierzbicki AS. Non-ceruloplasmin-bound copper in routine clinical practice in different laboratories. J Trace Elem Med Biol. 2008;22(1) :50-3

107. Wierzbicki AS, Nishtar S, Lumb PJ, Lambert-Hammill M, Crook MA, Marber MS, Gill J. Insulin resistance phenotypes and coronary artery disease in a native Pakistani cohort. Int J Clin Pract. 2008 May; 62(5) :701-7

108. Reynolds TM, Mardani A, Twomey PJ, Wierzbicki AS. Targeted versus global approaches to the management of hypercholesterolaemia. J Roy Soc Health 2008; 128 (5) : 248-254

109. Wong M, Oakley SP, Young L, Jiang B, Wierzbicki AS, Panayi G, Chowienczyk P, Kirkham BW. Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann Rheum Dis. 2009 Aug; 68(8):1277-84

110. Twomey PJ, Wierzbicki AS, Reynolds TM, Viljoen A. The copper/caeruloplasmin ratio in routine clinical practice in different laboratories. J Clin Pathol. 2009 Jan;62(1):60-3

111. Costa N, Paramanathan S, MacDonald D, Wierzbicki, AS, Hampson G. Factors regulating circulating vascular endothelial growth factor (VEGF): Association with bone mineral density (BMD) in post-menopausal osteoporosis . Cytokine 2009; 46 (3): 376-381

112. Manghat P, Fraser WD, Wierzbicki AS, Fogelman I, Goldsmith DJ, Hampson G. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int. 2010 Nov; 21(11):1853-61

113. Baldwin EJ, Gibberd FB, Harley C, Sidey MC, Feher MD, Wierzbicki AS. The effectiveness of long-term dietary therapy in the treatment of adult Refsum disease. J Neurol Neurosurg Psychiatry. 2010 Sep; 81(9):954-7

114. Aboud M, Elgalib A, Pomeroy L, Panayiotakopoulos G, Skopelitis E, Kulasegaram R, Dimian C, C Lampe F, Duncan A, Wierzbicki AS, Peters BS. Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study. Int J Clin Pract. 2010 Aug; 64(9):1252-9

115. Wierzbicki AS, Morrell J, Hemsley D, McMahon Z, Crook MA, Wray R. The effect of fibrate-statin combination therapy on cardiovascular events: a retrospective cohort analysis. Curr Med Res Opin. 2010 Sep; 26(9):2141-6

116. Davies JB, Crook MA, Wierzbicki AS, Goldsmith DJ. The incidence of low eGFR and proteinuria in a large tertiary referral lipid clinic. Int Urol Nephrol. 2011 Sep; 43(3):821-5

117. Elgalib A, Aboud M, Kulasegaram R, Dimian C, Duncan A, Wierzbicki AS, Peters BS. The assessment of metabolic syndrome in UK patients with HIV using two different definitions: CREATE 2 study. Curr Med Res Opin. 2011 Jan;27(1):63-9

118. Manghat P, Souleimanova I, Cheung J, Wierzbicki AS, Harrington DJ, Shearer MJ, Chowienczyk PJ, Fogelman I, Nerlander M, Goldsmith DJ, Hampson G. Association of bone turnover markers and arterial stiffness in pre-dialysis chronic kidney disease (CKD). Bone. 2011 May 1; 48(5):1127-32.

119. Ara R, A Pandor, Stevens J, Rafia R, Ward SE, Rees A, Durrington PN, Reynolds TM, WierzbickiAS, Stevenson M. Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy? Eur J Prev Cardiol 2012 Jun;19(3):474-83

120. Wierzbicki AS, Pendleton S, McMahon Z, Dar A, Oben J, Crook MA, Botha AJ. Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study. Int J Clin Pract. 2011 Jun;65(6):713-5

121. Peters BS, Wierzbicki AS, Moyle G, Nair D, Brockmeyer N. The Effect of a 12-Week Course of Omega-3 Polyunsaturated Fatty Acids on Lipid Parameters in Hypertriglyceridemic Adult HIV-infected Patients Undergoing HAART: A Randomized, Placebo-Controlled Pilot Trial. Clin Ther. 2012: 34(1):67-76

122. Meek C, Wierzbicki AS, Jewkes C, Twomey PJ, Crook MA, Jones A, Viljoen A. Daily and intermittent Rosuvastatin 5mg therapy in statin intolerant patients: an observational study. Curr Med



Res Opin. 2012; Mar;28(3):371-8

123. Salm MP, Horswell SD, Hutchison CE, Speedy HE, Yang X, Liang L, Schadt EE, Cookson WO, Wierzbicki AS, Naoumova RP, Shoulders CC. The origin, global distribution and functional impact of the human 8p23 inversion polymorphism. Genome Res. 2012 Jun;22(6):1144-53.

124. Clarke RE, Padayachee ST, Preston R, McMahon Z, Gordon M, Graham C, Crook MA, Wierzbicki AS . Effectiveness of alternative strategies to define index case phenotypes to aid genetic diagnosis of familial hypercholesterolaemia. Heart. 2013 Feb;99(3):175-80

125. Peters BS, Perry M, Wierzbicki AS, Wolber LE, Blake GM, Patel N, Hoile R, Duncan A, Kulasegaram R, Williams FM. A cross-sectional randomised study of fracture risk in people with HIV infection in the probono 1 study. PLoS One. 2013 Oct 29;8(10):e78048

126. Horswell SD, Fryer LG, Hutchison CE, Zindrou D, Speedy HE, Town MM, Duncan EJ, Sivapackianathan R, Patel HN, Jones EL, Braithwaite A, Salm MP, Neuwirth CK, Potter E, Anderson JR, Taylor KM, Seed M, Betteridge DJ, Crook MA, Wierzbicki AS, Scott J, Naoumova RP, Shoulders CC. CDKN2B Expression in Adipose Tissue of Familial Combined Hyperlipidaemia Patients. J Lipid Res. 2013 Dec;54(12):3491-505.

127. Walton TA, Nishtar S, Lumb PJ, Crook MA, Marber MS, Gill J, Wierzbicki AS. Angiographic coronary artery disease and high-sensitivity troponin-T in a native Pakistani cohort presenting with chronic chest pain. Int J Clin Pract. 2014 Dec;68(12):1473-7

128. Walton TA, Nishtar S, Lumb PJ, Crook MA, Marber MS, Gill J, Wierzbicki AS. Pro-protein convertase subtilisin/kexin 9 concentrations correlate with coronary artery disease atheroma burden ina Pakistani cohort with chronic chest pain. Int J Clin Pract. 2015 Jul;69(7):738-42.

129. Ewang-Emukowhate M, Harrington DJ, Botha A, McGowan B, Wierzbicki AS. Vitamin K and other markers of micronutrient status in morbidly obese patients before bariatric surgery. Int J Clin Pract. 2015 Jun;69(6):638-42.

130. Dodhia H, Kun L, Logan Ellis H, Crompton J, Wierzbicki AS, Williams H, Hodgkinson A, Balazs J.Evaluating quality and its determinants in lipid control for secondary prevention of heart disease and stroke in primary care: a study in an inner London Borough. BMJ Open. 2015 Dec 9;5(12):e008678.

131. Baldwin EJ, Harrington DJ, Sampson B, Feher MD, Wierzbicki AS. Safety of long-term restrictive diets for peroxisomal disorders: vitamin and trace element status of patients treated for Adult Refsum Disease. Int J Clin Pract. 2016 Mar;70(3):229-35.

132. Carroll C, Tappenden P, Rafia R, Hamilton J, Chambers D, Clowes M, Durrington P, Qureshi N, Wierzbicki AS. Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: AnEvidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2017 May;35(5):537-547.

133. Sankaralingam A, Thomas A, James DR, Wierzbicki AS. Assessment of a semi-quantitative screening method for diagnosis of ethylene glycol poisoning. Ann Clin Biochem. 2017 Jul;54(4):501-503.

134. Stepien KM, Wierzbicki AS, Poll-The BT, Waterham HR, Hendriksz CJ. The Challenges of a Successful Pregnancy in a Patient with Adult Refsum's Disease due to Phytanoyl-CoA Hydroxylase Deficiency. JIMD Rep. 2017; 33 :49-53.

135. Ramachandran R, Alaghband-Zadeh J, Sankaralingam A, Khan S, Tavabie M, Fernyhough C, Sabry M, Maghsoodi N, McGowan B, Carroll P, Wierzbicki AS. Sub-optimal rise in awakening inducedcortisol is an accurate marker of cortisol insufficiency in patients with normal renal function (eGFR > 60ml/min). Ann Clin Biochem. 2018 Jul;55(4):496-499

136. Neelamekam S, Kwok S, Malone R, Wierzbicki AS, Soran H. The impact of lipoprotein lipase deficiency on health-related quality of life: a detailed, structured, qualitative study. Orphanet J Rare Dis. 2017 Sep 19;12(1):156

137. Kohli M, Patel K, MacMahon Z, Ramachandran R, Crook MA, Reynolds TM, Wierzbicki AS. Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres. Int J Clin Pract. 2017 Nov;71(11). doi: 10.1111/ijcp.13032

138. Reynolds TM, Mewies C, Hamilton J, Wierzbicki AS; PATHFINDER Project Collaboration group. Identification of rare diseases by screening a population selected on the basis of routine pathology results-the PATHFINDER project: lysosomal acid lipase/cholesteryl ester storage disease substudy. J Clin Pathol. 2018 Jul;71(7):608-613

139. Reynolds TM, Wierzbicki AS. Demand management of weekend haematology and clinical biochemistry requests. Int J Clin Pract. 2018 Nov 25:e13297

140. Maghsoodi N, Shaw N, Cross GF, Alaghband-Zadeh J, Wierzbicki AS, Pinkney J, Millward A, Vincent RP. Bile acid metabolism is altered in those with insulin resistance after gestational diabetes



mellitus. Clin Biochem. 2019 Feb;64:12-17

To be submitted :-

Steinmetz AP, Cronin B, Wierzbicki AS, Lumb PJ, Maisey MN. Relationship of myocardial 18-FDG uptake on imaging in oncological PET imaging to plasma lipid and glucose metabolism.

Letters & Comments:

1. Wierzbicki AS, Cousins DM. Autoimmunity: a risk factor for allosensitisation to blood products. Brit Med J 1989; 298: 357

2. Wierzbicki AS. POEMS syndrome: further investigations on an unusual case. Brit J Hosp Med 1991; 46: 18

3. Wierzbicki AS. Molecular biology techniques in clinical chemistry. Ann Clin Biochem 1993; 30: 322-3

4. Wierzbicki AS. Paget's disease of bone. Brit Med J 1993; 303: 333

5. Wierzbicki AS. Bedside measurement of cardiac enzymes. Lancet 1993; 341: 890

6. Wierzbicki AS. Antibodies to L-type calcium channels in amyotrophic lateral sclerosis. New Engl Med J 1993; 328: 1355-6

7. Feher MD, Wierzbicki AS, Reynolds TM. Drug treatment of hypercholesterolaemia: establish diagnosis before treatment Brit Med J 1994; 308: 56

8. Wierzbicki AS. Maternal serum free beta hCG screening: results of studies including 480 cases of Down syndrome: problems with this approach. Prenatal Diagnosis 1994; 14: 1093

9. Wierzbicki AS, Bickel M, Reynolds TM. Glycated haemoglobin values: methodological discrepancies are not important. Brit Med J 1994; 308: 1511

10. Reynolds TM, Wierzbicki AS. The value of screening for secondary hyperlipidaemias in general practice. Brit Med J 1994; 308: 525

11. Wierzbicki AS, Reynolds TM. Health promotion in general practice: any beneficial effect was lost inbackground statistical noise. Brit Med J 1995; 310: 532-3

12. Wierzbicki AS, Reynolds TM. Implications of risk factor screening in general practice. Brit Med J 1995; 311: 263

13. Wierzbicki AS. Reynolds TM. Risk based prenatal screening for trisomy 18 using alpha-foetoprotein, unconjugated oestriol and human chorionic gonadotrophin: statistical flaws. Prenatal Diagnosis 1995; 15: 487-9

14. Wierzbicki AS, Reynolds TM. Sheffield risk and treatment table for cholesterol in lowering in prevention of coronary heart disease. Lancet 1996; 347: 466-7

15. Wierzbicki AS. Measurement of sodium-lithium countertransport kinetics. Hypertension 1996; 27: 314

16. Wierzbicki AS, Reynolds TM. Cost-effectiveness of lipid lowering: full treatment of the costs and benefits is needed. Brit Med J 1996; 313: 1143

17. Wierzbicki AS, Reynolds TM. Sheffield risk and treatment table for primary prevention of coronary heart disease. Lancet 1996; 348: 1039- 40

18. Wierzbicki AS, Reynolds TM. Cardiac troponin T in unstable angina: troponin T could be used to identify patients needing early treatment Brit Med J 1996; 313: 1330

19. Wierzbicki AS, Reynolds TM. Familial hyperchylomicronaemia. Lancet 1997; 348: 1524

20. Wierzbicki AS, Reynolds TM. Guidelines need to concentrate on reducing cardiovascular risk. Brit Med J 1997; 315: 1616

21. 103 Professors, consultants and specialists in preventive cardiology. Standing Medical Advisory Committee should reconsider advice to use Sheffield Risk table. Brit Med J 1997; 315: 1620

22. Reynolds TM, Wierzbicki AS, Crook MA, Capps NE. Effective health care: is it? Brit Med J 1998; 317: 80

23. Wierzbicki AS, Crook MA. Effect of atorvastatin on plasma fibrinogen. Lancet 1998; 351: 1430-1

24. Wierzbicki AS, Reynolds TM, Crook MA, Tatler J, Peters BS. Lipid lowering therapy in patients withHIV infection. Lancet 1998; 351: 1782

25. Wierzbicki AS, Reynolds TM. Cholesterol: how low is low enough? Doctors have been slow in getting evidence into practice. Brit Med J 1999; 318: 539

26. Wierzbicki AS, Crook MA, Reynolds TM, Jackson G. Thrombotic vascular events after change of statin. Lancet 1999; 353: 845



27. Hardman TC, Clifford RH, Wierzbicki AS. Erythrocyte Na+/Li+ countertransport and Na+/K+-2Cl- co-transport in essential hypertension. Clinical Science 1999; 97: 339-41

28. Hardman TC, Wierzbicki AS. Sodium-lithium countertransport and ethnicity. Am J Hypertens 1999;12: 433-4

29. Wierzbicki AS, Crook MA, Nair D, Mikhailidis DP, Winder AF. More on statins and fibrinogen. Atherosclerosis 2000; 148: 204

30. Wierzbicki AS, Crook MA. Cholestatic liver dysfunction. Lancet 1999; 354: 954

31. Wierzbicki AS, Reynolds TM. Cost effectiveness of statins. Heart 2000; 83: 713-4

32. Wierzbicki AS , Reynolds TM, Crook MA, Jackson G. Are drugs interchangeable? Lancet 2000; 355: 317

33. Wierzbicki AS, Crook MA, Mikhailidis DP, Winder AF. Natural statins and stroke. Circulation 2000; 101: E45

34. Reynolds TM, Wierzbicki AS. Is universal antenatal HIV screening ethical outside London? Bulletin Medical Ethics 2000; 152: 2

35. Wierzbicki AS, Swaminathan R. Coronary heart disease in Indian Asians. Lancet 2000; 355: 1727-8

36. Reynolds TM, Wierzbicki AS. Classification of acute MI. Eur Heart J 2000; 21: 857-858

37. Reynolds TM, Wierzbicki AS. 'Avoided deaths' may not be useful for predicting mortality reductions from cancer. Brit Med J 2000; 321: 1471

38. Wierzbicki AS, Reynolds TM. Risk assessment for cardiovascular disease. Brit Med J 2000; 321: 340

39. Reynolds TM, Wierzbicki AS. Statins and osteoporosis. Lancet 2000; 355: 1195

40. Wierzbicki AS, Reynolds TM. Statins and fractures. Lancet 2001; 357: 1887

41. Hardman TC, Wierzbicki AS. Erythrocyte sodium-lithium countertransport in African American women. J Hum Hypertens. 2001; 15: 505-506

42. Mikhailidis DP, Wierzbicki AS, Reynolds TM. Is a mechanical or a metabolic approach superior in the treatment of coronary disease? Results of the atorvastatin versus revascularization (AVERT) trial. Eur Heart J 2001; 22: 972-973

43. Wierzbicki AS, Crook MA, Reynolds TM, Mikhailidis DP. Measurement of atherosclerosis progression. Lancet 2001; 358: 328-329

44. Wierzbicki AS, Reynolds TM, Mikhailidis DP. Do you believe in MIRACLs? JAMA 2001; 86: 532-533

45. Reynolds TM, Wierzbicki AS. Does Evidence-Based Medicine Provide Evidence? The Evidence on Breast Cancer and the Safety of Oral Contraceptives Suggests that Unorthodox Interpretations may be just as valid. Breast J 2003; 9 : 66-67

46. Reynolds TM, Twomey P, Wierzbicki AS. Accuracy of Cardiovascular Risk Estimation. Clin Chem. 2003; 49: 706-707

47. Wierzbicki AS, Mikhailidis DP, Reynolds TM. More on PROSPER. Lancet 2003; 361: 1135-1136

48. Wierzbicki AS, Reynolds TM. Cost utility of pre-natal diagnosis. Lancet 2004; 363; 1165

49. Wierzbicki AS, Twomey PJ, Reynolds TM. Use of coronary calcification scores to predict coronary heart disease. JAMA 2004; 291: 1831

50. Wierzbicki AS, Twomey PJ, Reynolds TM. Screening for cardiovascular disease. Eur Heart J 2004; 25: 996

51. Wierzbicki AS. Clinical significance of oxidation from phytol to phytanic acid in man. Mol Genet Metab 2004; 83: 347

52. Jackson G, Solomon H, Wierzbicki AS. Erectile dysfunction and silent ischemia in type 2 diabetes mellitus. Circulation 2004; 111: e18-9

53. Twomey PJ, Viljoen A, Reynolds TM, Wierzbicki AS. Biological Variation in HbA1c Predicts Risk ofRetinopathy and Nephropathy in Type 1 Diabetes: Response to McCarter et al. Diab Care. 2004; 27: 2569

54. Wierzbicki AS, Twomey PJ, Reynolds TM. Cardiovascular risk assessment. Lancet. 2005; 365: 1305-1306

55. Wierzbicki AS. Ezetimibe-induced hyperlipidaemia- reply. Int J Clin Pract. 2005; 59:867-868

56. Twomey PJ, Viljoen A, House IM, Reynolds TM, Wierzbicki AS. Very low plasma copper levels do



not automatically imply severe copper deficiency. Ann Clin Biochem. 2005; 42: 405

57. Schachter M, Wierzbicki AS. Spinning stars; ASTEROID’s impact on atherosclerosis. Lancet 2006; 367: 1655

58. Twomey PJ, Viljoen A, House IM, Reynolds TM, Wierzbicki AS. Limitations of non-ceruloplasmin bound copper in clinical practice. Gut 2007; 56 : 154

59. Reynolds TM, Wierzbicki AS, Twomey PJ. Epidemiological studies are meaningless without proof of long-term data stability. Am J Med. 2008 Feb;121(2):e7

60. Athyros VG, Wierzbicki AS. Statin-fibrate combination therapy is safe and effective in normalizing lipid profile and in keeping cardiovascular event rates low. Curr Med Res Opin. 2014 Jan;30(1):57-8

Abstracts and Presentations:

1. Wierzbicki AS, Lang B, Beeson DMW, Newsom-Davis J. Multiple voltage gated calcium channel alpha 2 subunits in different tissues. Euromyasthenia, June 1991, Oxford J Autoimmunity 1992; 4 : v

2. Gilois C, Wierzbicki AS, Hirani N, Norman PM, Jones SJ, Ponsford SP, Alani M, Kriss AW. The haematological and electrophysiological effects of vegetarian diets. Vitamins: new aspects of deficiency; Arlington, Virginia, U.S.A., February 1992. Conference proceedings

3. Wierzbicki AS, Beeson DMW, Lang B, Newsom-Davis J. Tissue diversity of 2- subunit gene of the voltage gated calcium channel in rodent tissues and cell lines. Myasthenia gravis and myasthenic syndromes: new concepts in diagnosis and treatment. Washington DC, U.S.A., April 1992. Conference proceedings

4. Wierzbicki AS. Isolation and characterisation of the genes encoding the voltage gated calcium channel affected by Lambert-Eaton myasthenic syndrome antibodies in NG108-15 cells. Medical Research Society (Spring meeting 1992). Clinical Science 1992; 84 suppl 1: abstract 102

5. Wierzbicki AS, Beeson DMW, Lang B, Newsom-Davis J. Partial molecular characterisation of the calcium channel 2- subunit gene in the NG108-15 rat glioma/mouse neuroblastoma cell line affected by Lambert-Eaton myasthenic syndrome IgG. International Union of Biochemistry: the biochemistry of disease, Nagoya, Japan, 1992 Conference proceedings

6. Wierzbicki AS, Patel N, Evans K, Lascelles PT. 64Copper metabolism in two patients with non-Wilsonian low copper movement disorders. Medical Research Society. Clinical Science 1993; 85 suppl 2: abstract 97

7. Gilois CR, Hirani N, McCafferty R, Wierzbicki AS. Measurement of cobalamin & red cell folate: a comparison of chemiluminescent and radio-isotopic methods. Integrated systems for the clinical laboratory - effectiveness and impact of the clinical laboratory. ATB '92 Meeting, Milan 1992. Conference proceedings

8. Wierzbicki AS, Patel N, Evans K, Lascelles PT. 64Copper metabolism in two patients with non-Wilsonian low copper movement disorders. Association of Clinical Biochemists National Meeting Focus '93. Proc ACB National Meeting 1993; 54 : B29

9. Wierzbicki AS, Beeson DMW, Lang B, Newsom-Davis J. Characterisation of a putative candidate antigen for Lambert-Eaton myasthenic syndrome. Association of Clinical Biochemists National Meeting Focus '93. Proc ACB National Meeting 1993; 54: Ames award presentations, 4

10. Gilois CR, Wierzbicki AS, Lai AP. The role of anti-coagulant protein screening in patients with transient ischaemic attacks and unusual cerebral thromboses. 2nd International Congress on Stroke, Geneva, 1993. Conference Proceedings

11. Wierzbicki AS, King A, de Belleroche J, Mayne PD, Sidey M, Gibberd FB. Exclusion of linkage of Refsum's disease to major dominant loci associated with retinitis pigmentosa. Clinical Science 1994; 86 suppl 1 : 29P 93

12. Wierzbicki AS, King A, de Belleroche J, Mayne PD, Sidey M, Gibberd FB.Exclusion of linkage of Refsum's disease to major loci associated with retinitis pigmentosa. J Cell Biol 1994; 18A : 521

13. Wierzbicki AS, Ball SG, Singh NKR. Profound hyponatraemia following an idiosyncratic reaction todiuretics. Proc ACB National Meeting (1994) 55 : B2

14. Wierzbicki AS, King A, de Belleroche J, Mayne PD, Sidey M, Gibberd FB. Exclusion of linkage of Refsum's disease to major loci associated with retinitis pigmentosa. Proc ACB National Meeting 1994;79 : B58

15. Wierzbicki AS, King A, de Belleroche J, Mayne PD, Sidey M, Gibberd FB. Exclusion of linkage of Refsum's disease to loci associated with retinitis pigmentosa Muscle & Nerve 1994; 18 suppl 1 : S231 abstract 21-2-16

16. Wierzbicki AS, Nimmo L, Feher MD, Cox A, Foxton J, Lant AF. Association of the angiotensin converting enzyme DD genotype with hypertension in diabetes. London Hypertension Society 1995;



Conference Proceedings

17. Hardman TC, Croft P, Barlow R, Wierzbicki AS, Feher MD, Lant AF. Ethnic origin and hypertension associated alterations in sodium-lithium countertransport (SLC) kinetics. London Hypertension Society 1995; Conference Proceedings

18. Wierzbicki AS, Nimmo L. Angiotensin-converting enzyme genotyping: methodological pitfalls. London Hypertension Society 1995; Conference Proceedings

19. Hardman TC, Croft P, Barlow R, Wierzbicki AS, Feher MD, Lant AF. Ethnic origin and hypertension associated alterations in sodium-lithium countertransport (SLC) kinetics. Medical Research Society 1995; Conference Proceedings, Clinical Science 1995; 87 suppl 2

20. Wierzbicki AS, Nimmo L. Ambiguities in angiotensin-converting enzyme genotyping: a comparisonbetween two methods. American Society of Hypertension ASH ‘95 New York Am J Hypertens 1995; 7suppl 2

21. Hardman TC, Barlow R, Croft P, Wierzbicki AS, Dubrey S, Feher M, Lant AF.Relation between altered sodium-lithium countertransport kinetics and severity of vascular disease. European Atherosclerosis Society (1995). Utrecht. Conference proceedings. Atherosclerosis 1995; 67 suppl 1

22. Cummings MH, Christ E, Umpleby AM, Albany E, Wierzbicki AS, Lumb PJ, Sonksen PH, Russell-Jones DL. Hepatic secretion of very-low density lipoprotein apolipoprotein B-100 is increased in adult growth hormone deficiency: a stable isotope study. 10th International Congress of Endocrinology, 1996; proceedings:

23. MacGregor CAJ., Hanson MR, Das I, Laycock JF, Carter G, Hardman TC, Wierzbicki AS, Lant AF,Alaghband-Zadeh J. Raised plasma nitrate and nitrate concentrations in treated hypertensive subjects. Medical Research Society, Spring 1995; Cambridge. Clinical Science 1995; 87 suppl 2:

24. Hardman TC, Wierzbicki AS, Lant AF. ACE gene polymorphism and the erythrocyte sodium-lithium countertransporter phenotype in patients with hypertension. London Hypertension Society Abstracts 1996;

25. Hardman TC, Wierzbicki AS, Morrish Z, Lant AF. Effects of familial hypertriglyceridaemia on the kinetics of erythrocyte sodium -lithium countertranspport. Fatty acids and coronary Disease, Maastricht 1996; Prostaglandins & Leukotrienes 1996; 10 Suppl 1

26. Hardman TC, Wierzbicki AS, Morrish Z, Lant AF. Effects of familial hypercholesterolaemia on the kinetics of the erythrocyte sodium-lithium countertransporter. European Atherosclerosis Society 96. Atherosclerosis 1996; 126 suppl 1

27. Hardman TC, Morrish Z, Wierzbicki AS, Lant AF. Kinetics of the erythrocyte sodium-lithim countertransporter in treated familial hyperlipidaemias. European Atherosclerosis Society ‘96 . Atherosclerosis 1996; 126 suppl 1

28. Hardman TC, Wierzbicki AS, Patel S, Morrish Z, Lant AF. Erythrocyte sodium-lithium countertransport (SLC), leptin expression, insulin resistance and fat mass in treated dyslipidaemic patients. ASH ‘97 San Francisco. Am J Hypertens 1997; 10 suppl 1

29. Wierzbicki AS, Lumb PJ, Cheung J, Crook MA. Fenofibrate-simvastatin therapy compared to simvastatin-resin therapy and atorvastatin for familial hypercholesterolaemia. International Atherosclerosis Society 1997 Atherosclerosis

30. Ritter JM, Chowienczyk PJ, Gopaul NK, Brett SE, Wierzbicki AS. Dietary L-arginine reduces oxidative stress and restores endothelial function in men with coronary artery disease. Nitric Oxide (NO) ‘97 Ohstu Japan 1997

31. Wierzbicki AS, Hardman TC, Lumb PJ, Lant AF. Triglycerides not insulin resistance principally determine sodium-lithium countertransport activity in patients with familial hyperchylomicronaemia. ASH ‘98 Am J Hypertens 1998; 11 suppl 2 : 156A- F012

32. Mikhailidis DP , Wierzbicki AS, Lumb PJ, Nair DR, Semra YK, Papadakis JA, Jagroop IA, Crook MA, Winder AF. Atorvastatin reduces LDL-cholesterol but has unpredictable effects on lipoprotein (a). DALM 98; Atherosclerosis 1998; in press

33. Wierzbicki AS, Mikhailidis DP, LumbPJ, Nair DR, Semra YK, Papadakis JA, Jagroop IA,. Crook MA,Winder AF. Atorvastatin reduces LDL-cholesterol but increases another risk factor : fibrinogen. DALM ‘98; Atherosclerosis 1998; in press

34. Wierzbicki AS, Lambert-Hammill M, Mitchell J, Burston D, Greenwood J, Sidey MC, de BellerocheJ, Gibberd FB. Genetic heterogeneity in Refsum’s Disease. 48th Annual Meeting American Society of Human Genetics. Am J Hum Genet 1998 63 suppl : A277 (1598)

35. Wierzbicki AS, Lumb PJ, Semra YK, Crook.MA. A theoretically LDL-reduction matched comparison of atorvastatin with previous therapy: a clinical observational study. Cardiovascular Prevention IV; Kensington, London 1998 abstracts no 14



36. Reynolds TM, Patel N, Crook MA, Wierzbicki AS. Comparison of a simple tool with established algorithms for decision making in primary prevention of coronary heart disease. Cardiovascular Prevention IV; Kensington, London 1998 abstracts no 15

37. Wierzbicki AS, Mikhailidis DP, Lumb PJ, Nair DR, Semra YK, Papadakis JA, Jagroop IA, Crook MA, Winder AF. Effects of atorvastatin on additional risk factors for cardiovascular disease: a clinical observational study. Cardiovascular Prevention IV; Kensington, London 1998 abstracts no 16

38. Steimetz A, Wierzbicki AS, Maisey MN. Role of hyperlipidaemia in determining image quality in oncologic PET scanning . Nuclear Medicine 1999

39. Lloyd G, Lumb PJ, Wierzbicki AS, Jackson G. The effects of tibolone HRT on post-prandial triglyceride response. Cardiovascular Prevention, Washington DC, USA 1999

40. Wark G, Wierzbicki As. Comparison of LDL uptake and anti-LDL receptor flow cytometric methodsfor diagnosis of familial hypercholesterolaemia. American Association of Clinical Chemistry New Orleans 1999

41. Wark G, Wierzbicki AS. Comparison of LDL uptake and anti-LDL receptor flow cytometric methodsfor diagnosis of familial hypercholesterolaemia. Association of Clinical Biochemistry, Manchester 1999

42. Wierzbicki AS, Cheung J, Qureshi V. Screening for apolipoprotein A-1 variants in patients with low HDL in a lipid clinic. American Association of Clinical Chemistry New Orleans 1999

43. Wierzbicki AS, Cheung J, Qureshi V. Screening for apolipoprotein A-1 variants in patients with low HDL in a lipid clinic. European Atherosclerosis Society Athens 1999

44. Lumb PJ, Junadi E, Lambert-Hammill-M, Wierzbicki AS. Development of an automated method for determination of lipoprotein lipase activity and comparison with a manual method. American Association of Clinical Chemistry New Orleans 1999

45. Wierzbicki AS, Lumb PJ, Semra YK, Chik G, Christ ER, Crook MA. Treatment to target efficacy of atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias. European Atherosclerosis Society Athens 1999

72. Lloyd MD, Mukherji M, Kershaw N, MacKinnon CH, Schofield CJ, Wierzbicki AS. Unnatural cosubstrate-based rescue of enzyme activity in Refsum’s disease resulting from a PAHX mutation. CIEM 2000; J Inher Metab Dis ; 2000; 23 suppl 1 : 258; 516-O

73. Wierzbicki AS, Mitchell J, Lambert-Hammill M, Sidey MC, Feher MD, de Belleroche J, Gibberd FB. Identification of a second locus for Refsum’s disease at chromosome 6q22-24. . CIEM 2000; J Inher Metab Dis 2000; 23 suppl 1 : 259; 518-O

74. Lloyd MD, Mukherji M, Kershaw N, MacKinnon CH, Schofield CJ, Wierzbicki AS. Unnatural cosubstrate-based rescue of enzyme activity in Refsum’s disease resulting from a PAHX mutation. CIEM 2000; Am J Hum Genet; 2000; 67 suppl 1 :

75. Wierzbicki AS, Mitchell J, Lambert-Hammill M, Sidey MC, Feher MD, de Belleroche J, Gibberd FB. Identification of a second locus for Refsum’s disease at chromosome 6q22-24. CIEM 2000; Am J Hum Genet; 2000; 67 suppl 1 :

76. Wierzbicki AS, Lloyd G, McGing EH, Cooper A, Jackson G. Tibolone reduces apolipoprotien C-3 levels in non-HDL lipoprotein fractions. Drugs & Lipid Metabolism 2001

77. Wierzbicki AS, Toor GS, Millaseau S, Ritter JM, Chowienczyk PJ. Pulse wave analysis and cardiovascular event risk prediction in patients with hypertension. . Drugs & Lipid Metabolism 2001

78. Wierzbicki AS, Watts GF, Cockcroft JC, Chowienczyk PJ, Ritter JM. Cardiovascular risk factors and endothelial dysfunction. . Drugs & Lipid Metabolism 2001

79. Solomon H, Man JW, Wierzbicki AS, Jackson G. Relation of erectile dysfunction to angiographic coronary artery disease. American Heart Association 2002 Chicago

80. Nishtar S, Gill JS, Wierzbicki AS. Smoking exposure in patients with and without angiographically coronary heart disease in a Pakistani population. J Am Coll Cardiol 2002; 39(9) Suppl B: 460B-461B.

81. Twomey PJ, Don-Wauchope AC, Wierzbicki AS, Reynolds TM. Treatment to target for HbA1c in diabetes: the effect of biological variation on quality assurance for clinic performance. Diabetic Medicine, 2003; 20 (Suppl. 2): 110.

82. Twomey P, Wierzbicki AS, Reynolds TM · Accuracy of cardiovascular risk estimation in patients without diabetes. Atherosclerosis 2002:3; 223.

83. Twomey PJ, Reynolds TM, Wierzbicki AS. Concordance Evaluation of Coronary Risk Scores -Implications for CHD Risk Screening. International Atherosclerosis Society 2003 Kyoto

84. Gibberd FB, Wierzbicki AS, Feher MD. Smell tests in Refsum’s disease. Congress Inborn Errors Metabolism 2003 Brisbane



85. Wierzbicki AS, Mayne PD, Lloyd MD, Burston D, Mei G, Sidey MC, Feher MD, Gibberd FB. Metabolism of phytanic acid and 3-methyl-adipic acid excretion in patients with adult Refsum’s disease. Congress Inborn Errors Metabolism 2003 Brisbane.

86. Fabricius M, Lumb PJ, Wierzbicki AS: Assessment of lipoprotein subfractions by apolipoproteinA-1 and B-100 profiles compared with cholesterol distributions. Atherosclerosis 2003; 169: 356

87. Twomey P, Reynolds T, Wierzbicki A. Concordance evaluation of coronary risk scores - implications for CHD risk screening. Atherosclerosis Supplements 2003: 4;108

88. Wierzbicki AS, Doherty E, Lumb PJ, Chik G, Crook MA. Efficacy of ezetimibe in patients with resistant familial hypercholesterolaemia. Atherosclerosis 2004; 175 : S4

89. Wierzbicki AS, Nishtar S, Lumb PJ, Lambert-Hammill M, Gill J. Relationship of metabolic syndrome as assessed by different definitions with coronary arterial disease in Pakistanis. Atherosclerosis 2005; 182 : S2

90. Wierzbicki S, Suryanaranan S, Lyttle K, Lumb PJ. Comparison of a novel automated assay with traditional triolein assay for determination of lipoprotein and hepatic lipase activities. Atherosclerosis 2005; 182 : S6

91. Wierzbicki AS, Ratcliffe C. The 2007 Heart-UK Survey of Lipid Clinics and Clinical Practice in the UK. Atherosclerosis 2008; 199: 234

Projects Grants

1. Charing Cross & Westminster Hospital Trustees 1990-1991

Sodium-lithium countertransport and hyperlipidaemia

2. Charing Cross & Westminster Hospital Trustees 1991-1992

ACE genetics and diabetes

3. National Kidney Research Fund: 1992-1995

Molecular genetics of renal stones

4. Special Trustees of Guy’s and St. Thomas’ 1992-1995

Molecular genetics of Refsum’s disease

5. Merck Sharp & Dohme 1995-2000

Acute effects of statins on cardiac blood flow : a PET study

6. Parke-Davis 1999-2002

Haematorheological effects of statins in familial hypercholesterolaemia

7. Wellcome Trust 2000-2003

Transgenomic Wave system for molecular biology

8. Biotechnology & Biological Sciences Research Council. 2001-2004

Molecular basis of Refsum's disease

9. Solvay Healthcare. 2001-2002

Effects of moxonidine on lipoprotein subfractions

10. EC Grant – 2002-2005

RDDPT (Refsum’s and fatty acid oxidation)

11. NIHR PhD project grant 2013-2016

Dietetic intervention on HIV lipodystrophy

Clinical Trials

Bristol-Myers-Squibb Comparison of 80mg Pravastatin IR vs. MR 1998-1999

Bayer Comparison of 400/800 g of cerivastatin with simvastatin 20/40mg in patients with hypercholesterolaemia 2000-2001

Fournier Comparison of fenofibrate 160mg vs. Atorvastatin 20mg CFEN-9704 2000- 2001

Oxford CTSU Heart Protection Study. A randomised double blind parallel multi-centre group placebo controlled study of simvastatin 20mg compared with simvastatin 80mg in patients with established cardiovascular disease. Site co-investigator with John Chambers (cardiology) 1999-2004

Laboratoires Negma Effects of dose range of NK-104 on plasma lipid profiles in patients with hypercholesterolaemia- 2001- 2002



Laboratoires Negma Effects of dose range of NK-104 on plasma lipid profiles in patients with mixed hyperlipidaemia- 2001- 2002

Merck, Sharp & Dohme Treatment to target with 20-80mg simvastatin in patients with moderate hypercholesterolaemia- 2001-2002

Astra-Zeneca Comparison of rosuvastatin 10-20mg vs. simvasatin 20/40mg or atorvastatin 10/20mg in patients with type 2 diabetes (ANDROMEDA) 2002

Merck-Sharp & Dohme ACHIEVE: Protocol # 041-02 A Worldwide, Double-Blind, Randomized, Placebo-Controlled Study of MK-0524A 2 g Coadministered with Intensive LDL-C Lowering Therapy Compared to Intensive LDL-C Lowering Therapy Alone on Carotid Artery Intima-Media Thickness (cIMT) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) 2004

Oxford CTSU Heart Protection Study-2/ Treatment of HDL to Reduce the Incidence of Vascular Events (HPS-2/THRIVE). A randomised double blind parallel multi-centre group placebo controlled study of niacin-laropiprant added to optimal LDL-C reduction therapy in patients with established cardiovascular disease. Site co-investigator with John Chambers (cardiology) – 1999-2004

SanofiAventis Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes (CRESCENDO). A randomised double blind parallel multi-centre group placebo controlled study of rimonabant in patients with established cardiovascular disease or at high cardiovascular risk. 2008-2009

SanofiAventis ETERNAL: A European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with dyslipidemia with or without other comorbidities: UK PI. 2009

Genzyme Effect of mipomersen in severe hypercholesterolaemia. A randomised parallel group two-arm multicentre phase III study of the effects of tha apoB antisense therapy on lipid parameters in patients with familial hypercholesterolaemia not achieving a LDL-C <5.2 mmol/L despite maximal therapy 2009-2010

Merck-Sharp Dohme A randomised double-blind active-controlled multicentre study of patients with primary hypercholesterolaemia and high cardiovascular risk who are not adequately controlled with atorvastatin 10mg: a comparison of the efficacy and safety of switching to co-administration ezetimibe and atorvastatin versus doubling the dose of atorvastatin or switching to rosuvastatin 2010

Oxford CTSU Heart Protection Study-3/ Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL). A randomised double blind parallel multi-centre group placebo controlled study of anacetrapib added to optimal LDL-C reduction therapy in patients with established cardiovascular disease. Site co-investigator with John Chambers (cardiology). 2012-

Amgen Randomised placebo controlled trial of AMG-145 in patients with familial hypercholesterolemia2013.

Amgen Further Cardiovascular Outcomes Research With PCSK9 Inhibition (AMG-145) in Subjects With Elevated Risk (FOURIER). With Prof Kennedy Cruikshank 2013 onwards

Pfizer. Randomised controlled trial of the efficacy of bococicumab in the prevention of cardiovascular events. 2014-2015

Akcea Evaluation fo volanesorsen in patients with familial chylomicronemia syndrome (CS7)

2017-

The Medicines Company. Randomised controlled trial of the efficacy of ALN-PCS in patients with sever hypercholesterolaemia. 2015-2016

International Scientific Grants: A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE). 2015-

Memberships National Institute for Health & Clinical Excellence

Member; Health Technology Appraisal- ezetimibe TA 132 (2009)

Member (co-opted); Familial Hypercholesterolaemia Guideline Development Group CG71 (2009-2010)

Member: Technology Appraisal Panel A (2010-2013)

Member : Elucigene & Lipochip Technology Appraisal Panel (DG2) (2011)

Chair : Lipids & Cardiovascular Risk Assessment Guideline Development Group (2012-2014)

Member: Specialised Therapies Technology Appraisal Panel (2013-)

Member & expert: Quality Standards (cardiovascular) Advisory committee 2014-2015



Member : Diagnostics Appraisal Committee (2015- )

Chair : Chronic Cardiac Failure Guideline Development Group (2015-2018)

Chair: Hypertension guideline development group (2017-)

Chair: Renal Impiairment guidelines suite guideline devlopment group (2018-)

Society Positions

Member, Simon Broome Research Trust for Familial Hyperlipidaemias

Member, National Committee; British Hyperlipidaemia Association 2000-2002

Secretary; British Hyperlipidaemia Association 2002-2003

Secretary Medical & Scientific Committee; Hyperlipidaemia Education & Research Trust (HEART-UK) 2003-2005

Trustee, Hyperlipidaemia Education & Research Trust (HEART-UK) 2003-

Chairman Medical & Scientific Committee; Hyperlipidaemia Education & Research Trust (HEART-UK)2005-8

Fellowships

Fellow: American Heart Association

Fellow: National Association for Clinical Biochemistry (USA)

Conference Chairmanships

Association of Clinical Pathologists Annual Meeting; Chemical Pathology Section London 1994

Association of Clinical Pathologists Annual Meeting; Chemical Pathology Section, Brighton 1999

Clinical Biochemistry of Lipids: Pathology 2000, Birmingham 2000

Association of Clinical Pathologists Annual Meeting; Chemical Pathology Section, London 2002

International Peroxisomes Meeting; Ghent, Belgium 2002

HEART-UK sessions at 2001; 2002; 2003; 2004 meetings

Working Groups/Consensus Panels

International group on management of low HDL in cardiovascular disease; Nice (France) 2000

National Consensus panel on statin-fibrate combination therapy; Birmingham, 2001

International consensus group on HDL-C, Berlin, 2004

International consensus group on the metabolic syndrome, Strasbourg, 2004

International consensus group on HDL-C and fibrates, Paris, 2003-4

International consensus group on the metabolic syndrome in Asians, Hong Kong 2004

National consensus panel on use of ezetimibe, 2004

International Consensus group on Familial Hypercholesterolaemia 2012-2013

US American Heart Association Consensus Statement group on familial hypercholesterolaemia 2013-2014

Invited Lectures

Tegelaers Lecture; Amsterdam Medical Centre 1998 Refsum’s Disease

Drug Information Agency: Brussels 1999 Molecular genetics and clinical trials

Pathology 2000; Birmingham UK: 2000 Lipids: What tests really help?;

Leuven University 2001 Refsum’s disease: new aspects

Association Clinical Pathologists 2001 2001 New aspects of atherosclerosis

8th Greek IAS meeting, Athens 2004 HDL-C and cardiovascular risk

5th Kosovo Congress of Cardiology, Pristina 2004 Managing cardiovascular risk

16th ASEAN Congress Cardiology, Bangkok 2004 Raising HDL-C

1st Metabolic Syndrome Congress, Berlin 2004 Raising HDL-C

Cardiology Update 2005, Davos 2005 Trials in hyperlipidaemia

Diabetes-UK, Glasgow 2005 Combination therapy and CHD

Biomedical Science Congress, Birmingham 2005 Molecular Diagnostics in Pathology

EASD, Athens 2005 Raising HDL-C in diabetes



8th Congress Interventional Radiology Europe, Nice 2005 Reducing progression of atheroma

Association Clinical Biochemists 2006 Statins for all

XIVth International Symposium on Atherosclerosis 2006 New drugs for hyperlipidemia

EAS (78th meeting; Hamburg) 2010 New drugs for hypetriglyceridaemia

Association Clinical Biochemistry (Harrogate) 2011 Treating cardiovascular risk

European Congress Clinical Pharmacology (Dresden) 2011 Statin side-effects

Association Clinical Biochemistry (Liverpool) 2012 Statins and muscle biochemistry

IAS (European meeting; Prague) 2012 Guidelines and LDL-Cholesterol

European Cardiovascular Pharmacology (Bucharest) 2012 Beyond statins

ESC Cardiovascular Clinical Trialists (Paris) 2012 Atherosclerosis and clinical trials

International Soc CVD Pharmacology (Prague) 2012 HDL and its actions

International Soc CV Pharmacology (Rome) 2013 Clinical trials beyond LDL-C

Editorial Boards

Gerontology 2000-

Current Medical and Research Opinion 2001-

Current Vascular Pharmacology 2001-

International Journal of Clinical Practice 2003- (section editor – cardiovascular)

Vascular Disease Prevention 2003-

Current Drug Therapy 2004-

BMC Gerontology 2004-

Open Atherosclerosis Journal 2008-

Societies:

British Hyperlipidaemia Association/HEART-UK

British Hypertension Society

American Association of Clinical Chemistry (National Association of Clinical Biochemistry USA)

American Heart Association (arteriosclerosis section)

International Atherosclerosis Society

London Hypertension Society

Society for Study of Inborn Errors of Metabolism

Other Relevant Information


Documents

PERSONAL INFORMATION Anthony Wierzbicki Head of … · Curriculum vitae Anthony Wierzbicki and Translational Biology, and Council on Lifestyle and Cardiometabolic Health. The Agenda